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Klebsiella pneumoniae is one of the top eight pathogens in hospitals, causing 
around 10% of hospital-acquired infections (nosocomial infections). It often 
produces extended-spectrum β-lactamase enzymes (ESBLs). This has led to 
numerous outbreaks, especially in intensive care, neonatal and surgical wards, 
associated with increases in morbidity and mortality. In order to reduce the 
number of infections caused by multi-resistant K. pneumoniae and improve 
standards of infection control within hospitals, there is extensive use of biocides 
as disinfectants and antiseptics. However this raises concerns that intensive 
exposure of hospital pathogens to biocides may result in the emergence of 
resistance not just to themselves but also to antibiotics. 
The reduced susceptibility to biocides and their relationship with resistance to 
antibiotics was assessed in this thesis. The susceptibility of 64 isolates of K. 
pneumoniae to five biocides preparations, Chlorhexidine (CHX), Benzalkonium 
chloride (BZK), Trigene, MediHex-4 (MH-4), Mediscrub (MS) and 17 antibiotics, 
were tested. The isolates of K. pneumoniae were collected from Royal Infirmary 
Hospital in Edinburgh (RIE) between 2006 and 2008 from different sites of 
infection. Antimicrobial susceptibility was tested by the agar double dilution 
method (DDM) and disc diffusion methods following the British Society for 
Antimicrobial Chemotherapy (BSAC) guidelines. 
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A few isolates of K. pneumoniae showed insusceptibility to cephalosporins, 
colistin, rifampicin, trimethoprim and penicillin but not to carbapenems. Biocide 
susceptibility testing showed that 57, 55 and 61 strains had reduced susceptibility 
to Chlorhexidine, Trigene and Benzalkonium chloride, respectively, but not to 
MediHex-4 and Mediscrub. The effect of efflux pumps were determined by 
carbonyl cyanide m-chlorophenylhydrazone (CCCP) (10mg/L), which decreased 
the MICs of Chlorhexidine and Medihex-4 by 2 – 128 fold but had no impact on 
the MICs of Benzalkonium chloride, Trigene and Mediscrub. 
Six isolates of K. pneumoniae were chosen for their varying sensitivity to 
Chlorhexidine (CHX), and were tested for their minimum bactericidal 
concentration (MBC) to biocides. The high MBCs of Mediscrub and Trigene, 
over 500-fold greater than the minimum inhibitory concentration (MICs), 
indicates that these compounds are mainly bacteriostatic. Conversely, the MBCs 
of Chlorhexidine and MediHex-4, which contains chlorhexidine, were less than 
10-times the MIC value indicating they are effective in killing the organism. 
However, this thesis showed how the killing capability of Chlorhexidine was 
hindered by the presence of organic matter, which compromised its effect.   
The relationship between reduced susceptibility to biocides and the carriage of 
antiseptic resistance genes, cepA, qacΔE1 and qacE was determined by 
polymerase chain reaction. The antiseptic resistance genes cepA, qacΔE1 and 
qacE were found in 56, 34 and 1 isolates respectively, and the levels of gene 
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expression were detected by the reverse transcription polymerase chain reaction 
(RT-PCR). 
These results have shown that there was a close link between carriage of efflux 
pump genes, cepA, qacΔE1 and qacE genes and reduced susceptibility to 
biocides. Most strains showed decreased susceptibility to Chlorhexidine, Trigene 
and Benzalkonium chloride and this correlated with the carriage of the cepA, 
qacΔE1 and qacE genes encoding efflux. There was no correlation between the 
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Introduction of Klebsiella pneumoniae 
The Klebsiella genus  
The genus Klebsiella,  a member of the Enterobacteriaceae family, Klebsiella 
was named after the German Microbiologist Edwin Klebs, who first described the 
bacterium in the 19
th
 century (Podschun and Ullmann, 1998, Vincent, 2004, 
Brisse et al., 2006) 
The Klebsiella genus comprises of the following species: K. pneumoniae, K. 
oxytoca, K. rhinoscleromatis, K. ozaenae, K. aerogenes, K. planticola, K. mobilis, 
K. terrigena, K. trevisanii and K. ornithinolytica. Klebsiella spp. are ubiquitous in 
our environment, commonly found in water, soil, sewage, drinking water, 
industrial waste and plants as commensal bacteria (Casewell and Phillips, 1977, 
Bagley, 1985, Vincent, 2004, Brisse et al., 2009). They are identified and 
differentiated according to their biochemical reactions (Bagley, 1985, Vincent, 










Klebsiella spp. are Gram-negative, rod-shaped, lactose fermenting, oxidase 
negative and non-spore forming bacteria (Figure 1). They are facultative 
anaerobic bacteria and non-motile (no flagella), although they possess 






Figure 1. Microscopy, K. pneumoniae is Gram-negative, non-motile, encapsulated 
and rod-shaped. (adapted from http://first6weeks.blogspot.co.uk/ ) (Last accessed 




Figure 2. Scanning electron micrograph of K. pneumoniae. (adapted from Centers 
for Disease Control and Prevention (CDC)/Janice Carr  http://www.cdc.gov/) 
(Last accessed 31 August 2011). 
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K. pneumoniae is lactose-fermenting, it appears as pink colonies on MacConkey 






Figure 3. K. pneumoniae on MacConkey agar plate is mucous and lactose positive 
colonies. (adapted from Wikimedia Commons 
http://commons.wikimedia.org/wiki/File:Klebsiella_pneumoniae_mucoid.jpg) 
(Last accessed 25 December 2011). 
 
Pathogenicity factors  
Klebsiella spp. has many characteristics that promote their virulence. Klebsiella 
spp. express two types of antigens on their cell surface, capsular antigen and 
lipopolysaccharide antigen. Both antigens play an important role in classification, 




I. Capsular Antigen 
The capsular polysaccharide antigen (CPS) is one of the most important 
virulence factors.  CPS antigen is a polysaccharide with 77 serotypes that 
promotes adherence and protects K. pneumoniae from phagocytosis and 
bacterial serum factors (Podschun and Ullmann, 1998, Chuang et al., 
2006). 
II. Lipopolysaccharide Antigen 
The Lipopolysaccharide antigen (LPS) consists of three components; the 
O antigen, the core oligosaccharide and lipid A. LPS has 8  serogroups and 
serves to protect K. pneumoniae from complement mediated killing 
(Podschun and Ullmann, 1998). 
III. Adhesins   
K. pneumoniae attaches and adheres to host cell by pili (fimbriae) in the 
early stages of infection.  K. pneumoniae  express  two types of pili; type 1 
pili which are the most common whilst type 3 pili are less common. There 
are three new types of Klebsiella adhesins that have been recently 
reported, CF29K adhesin, Aggregative adhesin and KPF-28 (Podschun 
and Ullmann, 1998, Brisse et al., 2006).  
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IV. Siderophores, Iron is an essential factor for bacterial growth in host   and 
K. pneumoniae secure their supply of iron by siderophores (Podschun and 
Ullmann, 1998). 
V. Serum Resistance (Podschun and Ullmann, 1998).  
VI. Cytotoxins, enterotoxins and haemolysin proteins (Podschun and Ullmann 
1998; Brisse, Grimont et al. 2006). 
 
Figure 4. Representative diagram of the pathogenicity factors  found in K. 
pneumoniae (Podschun and Ullmann, 1998).  
 
8 serogroups  
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Pathogenesis 
K. pneumoniae can colonise the skin, mouth, throat, pharynx and gastrointestinal 
tract of humans (Bagley, 1985, Vincent, 2004), K. pneumoniae is a common 
opportunistic pathogen for humans and animals; however, under certain 
circumstances it can cause diarrhoea by enterotoxin release and serious infections, 
including urinary tract infections, respiratory infections, soft tissue infections, 
septicaemia, liver abscesses and bacterial meningitis.  
Recently about 8% of hospital-acquired infections including hospital-acquired 
pneumonia are caused by K. pneumoniae, this figure indicates that K. pneumoniae 
is a significant nosocomial pathogen. It is generally a real pathogen although it 
also infects immunocompromised patients due underlying health problems e.g. 
diabetes mellitus, chronic pulmonary obstruction and malnourished alcoholics or 
those with invasive medical devices and those hospitalised for long term care 







During the last decade, the incidence of hospital-acquired infection caused by 
multidrug resistant strains has increased alarmingly (Reacher et al., 2000). As a 
contribution to this, the spread of multidrug resistant strains of K. pneumoniae is a 
worldwide problem and has impacted on the ability to deal with nosocomial 
infection. The incidence of hospital acquired infections has escalated and it is 
estimated that now 10% of all hospital acquired infections (HAI) are caused by K. 
pneumoniae (Vincent, 2004, Struve and Krogfelt, 2004). It has been reported that 
approximately 7% of nosocomial infections in the United States, Canada and 
Europe (Sahly and Podschun, 1997) are caused by this organism. Recently it is 
estimated that 9% of in-patients hospital in England and Wales have a hospital 
acquired infection (HAI). As result there are 300,000 infected patients, 5000 
deaths and cost National Health Service over £1 billion per year  
(NationalAuditOffice, 2004). K. pneumoniae is now among the top eight 
pathogens in hospitals (Vincent, 2004). The spread of multiresistant K. 
pneumoniae has lead to numerous outbreaks and has increased the morbidity and 
mortality rate (Jarvis et al., 1985, Jacoby and Medeiros, 1991, Gupta, 2002, 




K. pneumoniae has the ability to adapt to the hospital environment and survives 
longer than enteric bacteria on hands and on environmental surfaces compared to 
other. This ability has coincided with inadequate infection control procedures that 
facilitates cross-infection within hospitals which combined has allowed K. 
pneumoniae to emerge as an important hospital pathogen (Paterson and Bonomo, 
2005). As a result, the rate of Klebsiella carrier in hospitalized patients have 
increased markedly, 77% in the stool, 19% in the pharynx, and 42% on the hands 
of patients (Podschun and Ullmann, 1998). 
In the hospital environment HAIs can be transmitted through different routes 
including medical tools, equipments and contaminated hands. Hand contamination 
is the most common mode of transmission of K. pneumoniae between hospital 
workers and patients (Casewell and Phillips, 1977). On the other hand, frequent 
handwash with chlorhexidine and quaternary ammonium compounds (QACs) 
recorded a significant reduction of 98 – 100% in the number of patients infected 







Introduction of antibiotics 
Antibiotics are defined as natural substances produced by microorganisms that 
can kill or inhibit growth of other organisms. The accepted view now is that all 
selective antibacterials are classified as antibiotics and this definition will be used 
here. 
The history of antibiotics can be divided in two periods as shown below: 
Early history 
Antibiotic use began in ancient times, prior to the 19
th
 century, when people 
observed how to use natural treatment to control infections based on traditional 
medicine. Ancient Sumerian used beer soup mixed with snake skins and turtle 
shells to treat wounds and infections of patients, while Babylonian doctors used 
frog bile and sour milk as ointment to heal eye infections. In addition, more than 
3000 years ago, Egyptians, Chinese, Greeks and Indians used moulds, honey and 
herbs in medicine as healing agents to treat infected wounds, although they did 
not understand the connection between natural substances as anti-infection agents 





Many books have been written about antibiotics  by a wide range of people in the 
world from different cultures and in several languages, including Roman, Greek, 
Persian, Turkish, Arabic and Hebrew, which discussed how to control infections 
caused  microorganisms by using natural sources available during  the years 
(reviewed by Florey et al., 1949). 
 
Modern history 





 centuries. The modern era of antibiotics began in the late 1800s, when 
the germ theory of disease came to prominence, which linked the microorganisms 
as the causation agent to a variety of diseases. As a result, European scientists 
began to devote their time to searching for an effective medication that would 
eradicate diseases and their causation agents. Finally, at the beginning of the 20
th
 
century, scientists discovered the natural antibiotics produced by microorganisms 
and made progress in this area, several treatments for infections were introduced 






Table1. Summarized modern history of antibiotics 
Years Name of discoverer Name of discovery 
Early 20th century Paul Ehrlich pioneers "chemotherapy" 
1929 Alexander Fleming  demonstrates inhibition of 
bacterial growth with penicillin 
moulds 
Early 1930s Gerhard Domagk  discovers "prontosil" a prodrug to 
sulphanilamide 
1935 Gerhard Domagk Sulfanilamide, the first synthetic 
sulfonamide in human medicine 
1942 Florey and Chain First therapeutic use of penicillin 
1944 Selman Waksman Streptomycin 
1947 David Gottlieb Chloramphenicol, the first broad-
spectrum antibiotic 
1948 Benjamin Dugger Chlortetracycline 
1960 Giuseppe Brotzu Cephalosporins 
1962 George  Lesher  discovers nalidixic acid during 
chloroquine synthesis 
1970s George Lesher  New 4-quinolones (pipemidic 
acid, oxolinic acid, cinoxacin) 
1980 Kyorin Seiyaku K.K. Norfloxacin, the first 
fluoroquinolone 
1980  Grohe and Peterson Enrofloxacin synthesized 
 1990s Pharmacia Company  Linezolid 
The table adapted from baytril.com.auhttp://baytril.com.au/Product/History.aspx 
(Last accessed   05 July 2010). 
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The first pioneer in this area was Paul Ehrlich, a German medical scientist, who 
first studied the interaction of different substances with microbial infections, and 
this the treatment of the infectious disease became known as chemotherapy 
(reviewed by Neu and Gootz, 1996).  In 1877 Louis Pasteur, a French chemist and 
Robert Koch a German physician, observed that bacteria can cause many diseases 
and bacteria can kill other bacteria. In 1905 Robert Koch was awarded the Nobel 
Prize in Medicine for his efforts in tuberculosis research (Figure 5) (reviewed by 
Neu and Gootz, 1996).  
 





Figure 5. Robert Koch (1843 – 1910) and Louis Pasteur (1822 – 1895). All 




In 1935, a German bacteriologist, Gerhard Domagk (1895 – 1964), introduced 
sulfonamides (Prontosil) as the first in vivo treatment against bacterial infections 
in commercial use. In 1939, Domagk received the Nobel Prize  in Physiology and 






Figure 6. Gerhard Domagk (1895 – 1964). The image is credited to official 
website of Nobel Prize http://www.nobelprize.org (Last accessed 02 March 2013). 
The great promise of antibiotics in their modern history was first demonstrated in 
1929 when Sir Alexander Fleming (1881 – 1955), a Scottish bacteriologist,  while 
working at St. Mary's Hospital in London, discovered penicillin accidently. 
Fleming noticed that a mould called Penicillium notatum inhibited the growth of 
the bacterium Staphylococcus aureus. He found that a clear zone had been 
developed around the mould indicating that penicillin moulds had produced a 
toxic substance that diffused through the agar and inhibited the growth of bacteria 
in vitro.  
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This lead to the hypothesis that penicillin can produce small molecular weight 
antibacterial chemicals, which could kill bacteria inside the body (Figure 7) 
(Rolinson, 1998, Bennett and Chung, 2001, Goldsworthy and McFarlane, 2002, 
Geddes, 2008). 
 
    
Figure 7. Fleming's original agar “Staph” plate with large mass of mould on left 
the produced penicillin. While numerous bacterial colonies grew at the edge of 
plate, a clear zone of inhibition of bacterial growth surrounds the mould colony 
where penicillin has released into the medium. (adapted from Accelr8.com 






In 1942 Howard Florey (1898 – 1968) and Ernst Chain (1906 – 1979), who 
headed a team of researchers at the University of Oxford, demonstrated the 
bactericidal action of penicillin inside the human body. Additionally, they 
succeeded in purifying a large quantity of penicillin from Penicillium notatum. 
This was the first antibiotic available for commercial and clinical use. This was 
the first step towards the modern antibiotics. During World War II, penicillin was 
used widely against many types of bacteria and had saved millions of lives, 
showing itself to be safe and effective antibiotic (Goldsworthy and McFarlane, 
2002). In 1945, Alexander Fleming shared the Nobel Prize  in Physiology and 
Medicine with Howard Florey and Ernst Chain for their work on penicillin 
(Figure 8)(Goldsworthy and McFarlane, 2002). 
 
Figure 8.  
Sir Alexander Fleming Sir Howard Florey  Sir Ernst Chain 
     (1881 – 1955)                            (1898 – 1968)        (1906 – 1979) 
All images are credited to official website of Nobel Prize   
http://www.nobelprize.org  (Last accessed 02 March 2013). 
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Shortly afterwards, the first of the aminoglycoside class of antibiotics was 
discovered and developed. In 1944, Selman Waksman (1888 – 1973), an 
American microbiologist, discovered streptomycin from the soil bacteria 
Streptomyces griseus. Streptomycin was the first antibiotic used to treat 
tuberculosis (Kingston, 2004). Five years later, in 1949, Waksman and his 
coworkers discovered a new aminoglycoside antibiotic called neomycin, a 
bactericidal antibiotic used commonly for skin infections. In 1952 he was received 
the Nobel Prize in Physiology and Medicine for his discovery of streptomycin and 





Figure 9. Selman Waksman (1888 – 1973). The image is credited to official 
website of Nobel Prize http://www.nobelprize.org (Last accessed 02 March 2013). 
Since penicillin, the first β-lactam antibiotic, was launched for commercial use in 
1942, many new classes of antibiotics have been discovered in the 1950s and 
1960s, such as aminoglycoside, chloramphenicol, tetracycline, chlortetracycline, 
erythromycin, vancomycin, rifampicin and cephalosporines (Table 1) (Rolinson, 
1998, Kingston, 2004). 
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Classification of antibiotics  
Fundamentally, antibiotics are classified based on several characteristics; such as  
I. Laboratory behaviour or Lethality 
a. Bactericidal antibiotics that have the ability to kill bacteria. 
b. Bacteriostatic antibiotics that preventing bacterial growth. 
 
II. Spectrum of activity 
a. Broad spectrum antibiotics affect a wide range of bacteria. 
b. Narrow-spectrum antibiotics that active against a limited range of 
bacteria. 
 
III. Mechanism of action 




Mechanism of action 
There are five main antibiotics targets on the bacteria: (Table 2 and Figure 11) 
(reviewed by Amyes, 2010).  
I. This group antibiotics interfere with the cell wall synthesis  
A group of antibiotics contains β-lactam ring, prevents cell wall 
production by blocking the cross linking of the polysaccharide chains to a 
new cell wall subunits, causing bacterial cell death. 
II. This group antibiotics inhibit the protein synthesis  
Disrupts protein synthesis by binding to the subunit of the bacterial 
ribosomes (30S or 50S subunit). 
III. This group antibiotics interfere with the nucleic acid (DNA) synthesis 
Interferes with DNA transcription and replication by targeting DNA 
gyrase and topoisomerase IV. 
IV. This group antibiotics interfere the ribonucleic acid (RNA) synthesis  
Disrupts RNA transcription by acting on DNA-directed RNA polymerase, 




V. This group antibiotics inhibit the synthesis of essential metabolites 
enzymes  
Inhibits biosynthesis enzymes by disruption tetrahydrofolate syntheses 
pathway (tetahydrofolic acid). This prevents folic acid synthesis which is a 
compound essential for DNA synthesis. 
 
VI. This group antibiotics disrupt of bacterial membrane structure  bacterial  
Disrupts bacterial membrane structure by binding to lipopolysaccharide 
(LPS) in the outer membrane of bacteria (polymyxins, daptomycin).
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Table 2. The antibiotic classes and their mechanisms of action ( reviewed by Amyes, 2010, Findlay, 2011). 



























































































Ciprofloxacin, Norfloxacin  
Metronidazole 
 Nalidixic acid 
 
Inhibition of RNA 
synthesis  













   






















Antibiotic resistance   
The term antibiotic resistance usually refers to a change in susceptibility of an 
organism that no longer responds to treatment (Russell, 1999, Poole, 2002). This 
is typically noted as an increase in the minimum concentration of antibiotics 
required to inhibit bacterial growth. Antibiotic resistance can be considered one of 
the greatest challenge facing hospitals. In the US there are over 2 million 
nosocomial infections each year and about half of these are caused by resistant 
strains (Jones, 2001). 
Basically, bacteria have developed several ways to defend themselves against 
antibiotics as a means to survive resulting in the evolution and spread of bacterial 
resistance. Numerous and various mechanisms of antibiotic resistance have been 
reported for example, mutation, acquisition of genes via conjugation, reduced 
permeability, active efflux, inactive of the antibiotic via enzymatic destruction and 






Extended spectrum β-lactamases  
Originally, β-lactam antibiotics were frequently prescribed to treat these infections 
caused by K. pneumonia. These comprised mainly cephalosporins because this 
species is usually not considered clinically sensitive to aminopenicillins such as 
ampicillin and amoxicillin, despite the results of in vitro sensitivity tests. 
Extensive and imprudent use of antibiotics in clinical treatment may have been 
responsible for an increased prevalence of resistance ultimately leading to 
development of multidrug resistance. This has been most acutely manifested by 
the emergence of a group of enzymes called extended spectrum β-lactamases 
(ESBLs) as well as chromosomal mutation (Podschun and Ullmann, 1998).  
The first ESBL was detected in Germany in 1983 (Knothe et al., 1983). ESBLs 
have been detected in a wide variety of Gram-negative bacteria. ESBLs genes are 
usually encoded on plasmids and classified into TEM, SHV, OXA and CTX-M. 
All but OXA enzymes are class A β-lactamases, OXAs belong to class D.              
K. pneumoniae continues to be an important ESBLs producer (Livermore, 1995, 
Philippon et al., 2002, Canton et al., 2003, Schneiders et al., 2003, Poole, 2004, 





β-lactamases are able to break and hydrolyze the carbon-nitrogen bond of the 
β-lactam ring and deactivate these antibiotics as the planar β-lactam ring is no 
longer functional (Figure 11)(Livermore, 1995, Philippon et al., 2002, Poole, 
2004, Paterson and Bonomo, 2005). 
 





Figure 11. The core chemical structure of penicillin with β-lactam ring in red at 
the centre. 
The incidence of bacterial ESBL varies worldwide with low rates (3 – 8%) 
reported in Sweden, Japan and Singapore, compared to higher rates reported in 
Portugal (34%), Italy (37%), New York (44%), Latin American countries (30 –
60%) and Turkey (58%)(Khanfar et al., 2009). In the Gulf Cooperation Council 
(GCC) countries, ESBL rates range from 8.5 – 38.5% in the Kingdom of Saudi 
Arabia, 31.7% in Kuwait and the highest level in United Arab Emirates with 
41%.(Khanfar et al., 2009). 
 38 
Antibiotic resistance mechanisms  
The six main mechanisms that bacteria use to resist the action of antibiotics are 
presented in (Figure12) (reviewed by Russell, 2003, Amyes, 2010). 
 
I. Enzymatic modification or inactivation. Enzymes can destroy or modify 
antibiotic so the antibiotic will not be able to attack the target site. 
Resistance occurs by natural, mutational chromosomal genes or 
acquisition of extrachromosomal genetic elements (plasmids or 
transposons), for instance, β-lactamase enzymes destroys the β-lactam ring 
( Livermore, 1995, reviewed by Amyes, 2010). 
 
II. Impermeability features. Bacteria can reduce the susceptibility of the 
antibiotic agent by reducing the membrane permeability; for example, 
outer membrane proteins may act as channels that control antibiotic entry 






III. Acquisition of active efflux pump genes is a common mode of resistance. 
The presence these pumps may be lead to Multiple Drug Resistance 
(MDR). Multidrug-resistance efflux pumps families have become a great 
challenge in hospitals (Poole, 2002, Piddock, 2006b). These systems can 
be classified into five superfamilies based on the energy source used to 
export their substrates and the sequence of amino acid including (Table 3 
and Figure 12). 
1. The ATP binding cassette superfamily (ABC). 
2. The multidrug and toxic compound extrusion family 
(MATE).  
3. The major facilitator superfamily (MFS). 
4. The resistance nodulation cell division superfamily (RND).  
5. The small multidrug resistance family (SMR). 
The ABC superfamily is primary transporters, it utilize ATP as sources of 
energy for extrusion of antibiotics and toxic substances from the cell. The 
other families represent  secondary transporters is energized by protons or 
sodium ions (Zechini and Versace, 2009).  
The presence and activity of an efflux pump can be  demonstrated by 
efflux pump inhibitor (EPI) in vitro such as cyanide m- chlorophenyl 
hydrazone (CCCP), phenylalanine arginyl b β-naphthylamide (PAbN) and 
reserpine (Garvey and Piddock, 2008). 
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Table 3. A summary of the bacterial efflux pump families (Findlay et al., 2012).  
 





Figure 12. The five families of Multidrug-resistance efflux pumps (Piddock, 
2006b). 
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IV. Alteration of cellular target sites such as enzyme. Ribosome and cell wall 
is modified by acquiring a plasmid, transposons or mutation so that there 
is no longer a recognition site for the antibiotic. The consequence of these 
changes reduce the susceptibility to antibiotics, thus promote resistance 
(reviewed by Russell, 2003, Amyes, 2010). 
 
V. The inhibited steps can be by-passed. Bacteria can be developed an 
alternative metabolites pathway that may or may not disable the 
metabolites target for antibiotic and an additional target makes is less 
sensitive to the binding of the antibiotic. For example alternative pathway 
for folic acid synthesis (Amyes and Smith, 1974, reviewed by Russell, 
2003, Amyes, 2010). 
 
VI. Overproduction. The target can be produced in larger quantities than 
normal by the bacteria thus hyperproduction of the target will mop-up the 
antibiotic (reviewed by Russell, 2003, Amyes, 2010). 
 





Figure 13. Resistance mechanisms of bacteria to antibiotics (Coates et al., 2002) and reproduced with permission 
from the controller of her Majesty’s Stationary office. 
Inactivation 
The bacterium can inactivate an 
antibacterial before it enters the cell, 
e.g. penicillin-resistant bacteria 
produce β-lactamase which splits the 
penicillin molecule 
Impermeability 
The cell wall can became 
impermeable to antibacterias, 
e.g. streptomycin resistance  
Altered target 
The target of the antibacterial  
can  become altered so that  
it is no longer reconginsed,  
e.g. .in erythromycin resistance 
Efflux 
Bacteria can eliminate antibacterials 
via a pump mechanism,  
e.g. ciprofloxacin resistance 
 
Overproduction 
 the target can be produced in 
large quantities  than  normal by 
the bacteria thus hyperproduction  
of  target mop-up antibiotic 
Metabolic bypass 
Bacteria are also able to 
develop an alternative 
metabolic pathway,  
e.g. in trimethoprim 
resistance, even when the 
target pathway has been hit. 
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Introduction of biocides  
Biocide is a general term describing a chemical agent that has a broad spectrum 
activity, which is capable to inactivative or kill microorganisms (McDonnell and 
Russell, 1999). Biocides include disinfectants, antiseptics and preservatives 
(Russell, 1999).  
Disinfectant: This is a chemical agent that are applied on nonliving objects (e.g., 
floors, walls, sinks) to destroy microorganisms. Disinfectants are normally too 
toxic for human use and they are frequently used in food industry, veterinary 
application and clinical environments such as hospitals, dental surgeries to control 
the spread of infectious organisms (McDonnell and Russell, 1999). 
Antiseptic: This is a chemical agent that is used on skin or living tissue for 
inhibiting or destroying microorganisms. Antiseptics are less-toxic agents and 
commonly used for skin cleaning, handwashing, on wound surfaces and as 
surgical scrubs to eliminate a number of microorganisms. Examples of antiseptics 
include alcohol, chlorhexidine, chloroxylenol (PCMX), hydrogen peroxide, iodine 
compounds, triclosan and quaternary ammonium compounds such as 
benzalkonium chloride, cetrimide (McDonnell and Russell, 1999). 
Preservative: This is a compound that is often added to a medicine or food, which 
has previously been sterilised, to prevent microbial growth once the container is 
opened (McDonnell and Russell, 1999). 
 44 
Ideal properties of an antiseptic 
1. Broad antimicrobial spectrum. 
2. Bactericidal action. 
3. Longer antibacterial effects. 
4. Easy to use. 
5. Least adverse effects.  
6. Efficiency in the presence of organic matter (Cecilio et al., 1983). 
As a part of infection control strategies various types of disinfectants and 
antiseptics are utilized widely in hospital settings to reduce the incidence of 
nosocomial infections. 
 
Biocides, usage and mode of action 
The modes of action of biocides are less well known compared with antibiotics; 
however there are similarities between the two. The uses and the mechanisms of 
action of most common biocides, i.e. list them here, are provided in Table 4.  
These are the most frequent biocides used in local hospital, although there are 




Table 4. Some types of clinical biocide agents with their contents, main targets 
and use (McDonnell and Russell, 1999, reviewed by Russell, 2003). 
Biocides 
family 
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Chlorhexidine is a biguanide compound, cationic antiseptic and active agent 
against various types of bacteria. It has been used widely in Europe and United 
Kingdom hospitals (Fraise, 2002b) .  
 
Chlorhexidine Digluconate 20% in H2O 
Chlorhexidine digluconate 20% in H2O solution belongs to the biguanide family, 
it has been used as an antiseptic and disinfectant, It is broad-spectrum 
antimicrobial, bactericidal, virucidal and fungicidal (McDonnell and Russell, 
1999, reviewed by Russell, 2003). 
 
Use 
Chlorhexidine is mainly used for handwashing, skin cleansing, surgical scrub, 
antiplaque (oral rinses and mouthwash) and a preservative agent (Figure14) 





Mechanism of action  
Chlorhexidine is cationic and reacts with the anionic microbial cell surface, thus 
disrupting the cell membrane. Subsequently, chlorhexidine penetrates into the cell 
and causes leakages of intracellular constituents leading to cell death (Figure15) 
(McDonnell and Russell, 1999). Chlorhexidine is an effective biocide for Gram-
positive bacteria because they are more negatively-charged and have a single 
membrane; therefore Gram-positive bacteria are more sensitive to this agent 









Figure14. Chlorhexidine Digluconate 20% in H2O. 
Figure 15. Chemical structure of Chlorhexidine. 
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MediHex-4 solution  
The main ingredient of MediHex-4 solution is 4% of chlorhexidine; it is active 
against a wide variety of bacteria, fungi and viruses (Medichem International). 
Use 
MediHex-4 solution applies for hand cleaning and disinfection of the whole skin 
area, it is semi viscose liquid, red colour (Figure 16) (Medichem International). 
Mode of action  
MediHex-4 solution has the same mode of action of Chlorhexidine digluconate 
20% in H2O, because it contains 4% chlorhexidine. Positive charged has the 
ability to interact with the negatively charged of cell walls of bacteria and which 
increases permeability of membrane thus causing the death of the bacteria  
(McDonnell and Russell, 1999, reviewed by Russell, 2003). 







Figure 16. MediHex-4 solution. (adapted from Medichem International). 
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Trigene advance solution  
Trigene advanced solution, is a biguanide compound containing <1% polymeric 
biguanide hydrochloride and <1% didecyl dimethyl ammonium chloride and alkyl 
dimethyl benzyl ammonium chloride. Trigene is broad-spectrum disinfectant, 
bactericidal, sporicidal, mycobactericidal, virucidal and fungicidal (Medichem 
International). 
Use 
Trigene is appropriate for all surfaces , furnitures, equipments and also can be 
used for all medical areas in hospitals, clinics and dental clinics, Trigene solution 
is a blue colour liquid (Figure17) (McDonnell and Russell, 1999, reviewed by 
Russell, 2003) (Medichem International). 
 
Mode of action  
Trigene is based on the active ingredients of polymeric biguanide as cationic 
compounds and it is carried rapidly through the cell walls of bacteria, causing 
interruption of, and penetration through the bacterial outer membrane, which 
reduces its permeability and causing death to the cells (McDonnell and Russell, 
1999,  reviewed by Russell, 2003) (Medichem International).  
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Triclosan is a bis-phenol broad-spectrum disinfectant which is very active against 
a wide range of pathogenic organism (Fraise, 2002b). It is utilized commonly in 
hospital as detergents, surgical scrub, soap and hand gels. It is a key agent for 
disinfecting used against Gram-positive bacteria (Jones et al., 2000, Levy, 2001, 
Russell, 2004). 
Triclosan is made more effective by adding ethylenediamine tetraacetic acid 
(EDTA), which increases the permeability of the outer membrane of bacteria 
(McDonnell and Russell, 1999, (McDonnell and Russell, 1999, reviewed by 
Russell, 2003).  It should be noted that the EDTA has an antibacterial effect of its 
own. 
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Mediscrub solution  
Mediscrub solution contains 1% triclosan together with anionic and amphoteric 
surfactants. It is broad-spectrum antiseptic and effective against a wide variety of 
bacteria, viruses and fungi (Medichem International). 
Use 
Mediscrub is suitable for handwashing and cleansing. Mediscrub solution is a 
high viscosity liquid (sticky) with pink colour (Figure 18) (McDonnell and 
Russell, 1999, reviewed by Russell, 2003)  (Medichem International).  
 
Mode of action 
Mediscrub contains triclosan inhibiting fatty acid synthesis by binding to the 
enoyl-acyl carrier protein reductase enzyme (ENR), which is an essential enzyme 
for biosynthetic pathway fatty acid in bacteria. Consequently; the bacteria are 
unable to synthesis fatty acid, which is necessary for building cell membranes and 
for reproduction. As a consequence the outer membrane of bacteria impairs and 
increases the permeability. It also has an influence on the cytoplasmic membrane 
and destroys the cell effectively (figure 19) (Heath et al., 1999, McDonnell and 
Russell, 1999, Jones et al., 2000, reviewed by Russell, 2003, Russell, 2004)  











Figure 18. Mediscrub solutions. (adapted from Medichem International). 
 
 











Quaternary Ammonium Compounds (QACs) 
Quaternary Ammonium Compounds (QACs) are surface-active agents, cationic 
with very good activity against various types of clinical pathogenic organisms, 
non corrosive and low toxic properties. Quaternary ammonium compounds 
(QAC) are widely used as antiseptics and disinfectants in both medical and food 
environments. 
Benzalkonium chloride 
Benzalkonium chloride, a cationic surface-acting agent belonging to the 
quaternary ammonium compound group, is mainly active against Gram-positive 
bacteria, and it is the most useful disinfectant in hospitals (McDonnell and 
Russell, 1999, Fraise, 2002b) . 
Use 
Benzalkonium chloride is usually utilized in wide range of applications because it 
is an efficient and safe agent. It is used as antiseptics and disinfectants for skin, 
hand sanitizers, cleansing wounds and hard surfaces (Figure 20) (McDonnell and 





Mode of action 
Benzalkonium chloride is a cationic compound, which interacts with the inner 
membrane of bacteria mainly as it is negatively charged; then the agent penetrates 
into the cell wall, where it reacts with the cytoplasmic membrane and disrupts the 
integrity of the cytoplasmic membrane causing leakage of the intracellular content 
of cell and death (Figure 21) (McDonnell and Russell, 1999, reviewed by Russell, 
2003). 






Figure 20. Benzalkonium chloride. 
 
Figure 21. Chemical structure of Benzalkonium chloride. 
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Bacterial resistance to biocides  
The term resistance is used to describe bacterial insusceptibility to antimicrobial 
agents. According to Russell, (1999) the term “biocide resistance” is usually used 
to define a bacterial strain surviving exposure to a biocide concentration which 
kill the rest of the bacterial population.  
Biocides are used extensively in modern society as a part of sanitization, they are 
commonly used in hospitals to decontaminate skin, hands, wounds and surfaces, 
particularly in operation room as part of infection control to reduce and manage 
hospital acquired infection. However, there has been increased biocide use such as 
Chlorhexidine, Triclosan and Benzalkonium chloride for various ranges of 
applications e.g. skin antiseptics, hand sanitizers and surfaces cleaners. Several of 
these compounds are available for the general market, outside the direct medical 
field, and this widespread use had raised some concern on the development of 
bacterial resistance to biocides. 
The first biocide resistance was recognized 70 years ago in Salmonella typhi 
(Fraise, 2002a). Biocides resistance is less common than antibiotics resistance due 
to most of biocides having multiple modes action against microbes (Poole, 2002, 
Fraise, 2002b). Recently, there is increasing evidence that indicate the 
development of biocides resistance has become a significant risk and there are 
numerous reports concerning the problem (Fraise, 2002b, Maillard, 2007). 
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Factors affecting biocide activity 
Biocide activity is influenced by several factors: concentration, exposure time, 
pH, temperature, environments, presence of organic matter, interfering compound 
and the nature, number, location, and condition of the microorganism (Russell, 
2002, reviewed by Russell, 2003). 
 
I. Concentration, is a crucially important factor in assessing the effect of 
biocide activity. Concentrations lower than the recommended one have 
little bactericidal activity, which probably enables organisms to obtain 
some degree of resistance to an individual biocide (Stickler, 2002, 
reviewed by Russell, 2003).  In hospitals topping up of biocides solution, 
such as QACs and Chlorhexidine, leads to diluting the concentrated 
biocide and to incorrect use of biocides, all of which will reduce biocides 
susceptibility. 
 
II. Contact time, exposure of clinical isolates repeatedly and regularly to 
insufficient periods of time of biocide that bacteria could gradually 




III. pH, Many biocides have an optimum pH range.  Glutaraldehyde and 
cationic biocides as chlorhexidine and QACs are active at alkaline pH,  
whereas hypochlorites and phenolics are most potent at acid pH.  
 
IV. Interaction with organic matter, such as blood serum, pus and dirt can 
adversely affect the efficacy of many biocides.  
 
V. Environment of biocide residues, where bacteria could develop low-
level of insusceptibility.  
 
VI. Condition, phenotypic adaptation is one of the mechanisms of resistance 
for the bacteria to survive under constantly changing and stressful 
condition.  
It is assumed that biocides insusceptibility may be increasing. Furthermore, it is 
anticipated that biocides resistance will emerge on a major scale at some point in 
future (reviewed by Russell, 2003). 
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Biocides resistance mechanisms  
Biocide resistance can occur as a natural resistance of an organism to a biocide 
agent (Intrinsic) or acquired resistance (reviewed by Russell, 2003). 
Intrinsic Resistance mechanisms 
Intrinsic resistance is the innate ability of bacteria to resist the activity of a 
particular biocide agent. Intrinsic resistance is dependent on the natural 
insusceptibility or natural characteristic of the bacteria, which is demonstrated by 
a Gram-negative bacteria, spores, mycobacterium and S. aureus (reviewed by Neu 
and Gootz, 1996, Russell, 2003). Some bacteria can display intrinsic resistance 
through inactivation of biocides, alteration of the target site. Intrinsic resistance is 
usually chromosomally encoded (Gilbert and McBain, 2003). Intrinsic resistance 
can be:   
I. Impermeability, the outer membrane is very important factor in intrinsic 
resistance (Poole, 2002). The structure of the outer membrane of the cell 
may act as permeability barrier to reduce biocides entry to the bacterial 
cell, and change in this structure can include alteration of: surface 
hydrophobicity, outer membrane ultrastructures, outer membrane protein 
composition and outer membrane fatty acid structure (Figure 13) 
(McDonnell and Russell, 1999, reviewed by Russell, 2003). This type of 
intrinsic resistance is often demonstrated in Gram-negative bacteria. 
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II. Inactivation, some bacteria display resistance to QACs and chlorhexidine 
at lower concentration. Consistent exposure of sub-inhibitory 
concentrations of biocides may induce biocides degrading enzymes 
(McDonnell and Russell, 1999, reviewed by Russell, 2003). 
 
Acquired Resistance mechanisms 
Acquired insusceptibility may arise by altering the target sites, mutation, 
acquisition genetic elements (transposons or plasmid)(Russell, 2001). 
 
I. Overproduction of target, this does occur with triclosan where there is 
overproduction of enoyl-acyl carrier protein reductase enzyme (ENR) 
(McDonnell and Russell, 1999, reviewed by Russell, 2003). 
 
II. Alteration or modification of the target sites, biocides usually affect 
multiple cellular components (Poole, 2002); for example, triclosan 
resistance in Escherichia coli, is by modification by mutation of the enoyl-
acyl carrier protein reductase enzyme. The active target site for triclosan, 
which leads to failure of triclosan when it is used to treat E. coli 
(McDonnell and Russell, 1999, Levy, 2001, Poole, 2002, reviewed by 
Russell, 2003, Maillard, 2005). 
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III. Acquired plasmid mediated resistance is mainly associated with 
mercury compound and metallic salts (McDonnell and Russell, 1999). 
Resistance plasmids are more associated with antibiotic resistance than 
biocides resistance (Russell, 1997, Gilbert and McBain, 2003). Plasmid 
mediated resistances are not common in biocide insusceptibility; however, 
a direct association between Gram-negative bacteria plasmids and biocide 
resistance have been linked to efflux mechanisms (Gilbert and McBain, 
2003). Plasmids carrying efflux pump genes are the main resistance 
mechanism to cationic biocides such as chlorhexidine and QACs. 
 
IV. Acquired resistance may also occur through efflux pumps, which pump 
out biocides faster than they can enter (Levy, 2001).  The efflux pump is 
also known as the ‘vomit response’ allowing bacteria to remove toxic 
compound from cell (reviewed by Russell, 2003) and respond to stressful 
changes in the environment (Gilbert and McBain, 2003). Efflux pumps are 
located in the cell wall of bacteria and remove biocides from the cell, often 
lowering susceptibility to chlorhexidine and QACs (Suller and Russell, 
1999). It has proven to be an important survival strategy for most of 
bacteria  (Gilbert and McBain, 2003).  
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The efflux system acts as a transport for many antibiotics and biocides. 
Interestingly, efflux systems are able to accommodate biocides including 
QACs (Benzalkonium chloride) and Chlorhexidine in Gram-negative and 
Gram-positive bacteria (Kazama et al., 1998, Poole, 2002).  
Efflux pump genes can be carried and transmitted via plasmids in both 
Gram-negative and Gram-positive bacteria (Gilbert and McBain, 2003, 
Fraise, 2002b). Therefore, there is a possibility of cross linking between 
biocide resistance genes and antibiotics resistance genes. It is also 
theoretically possible that the efflux mechanisms involved in the low level 
resistance to Chlorhexidine (Russell, 1997), could also confer resistance to 
antibiotics (Fraise, 2002b). QACs resistance genes are classified into two 
main families; (a) the qacA/B genes, which are members of the 
multifacilitator superfamily, and (b) qacC/D, qacE, and qacE∆1 genes, 
which belong to the small multidrug resistance family (Paulsen et al., 
1996).  
The multidrug resistance qacE gene was initially identified on the 
Klebsiella aerogenes plasmid R751, where it is located on an integron 
(Paulsen et al., 1996, Kazama et al., 1998). The qacE and qacE∆1 
(disrupted form of qacE) are located  either on plasmids or on Class I 
integrons (Paulsen et al., 1996).  
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qacE∆1 gene is distributed widely through Gram-negative bacteria 
because it is often located on the ubiquitous Class I integron and the 
spread of this integron may have been facilitated by the use of quaternary 
ammonium compounds (Kazama et al., 1998, Kucken et al., 2000, 
Schneiders et al., 2008). The cepA efflux gene has been detected on one 
occasion in a clinical isolate of K. pneumoniae, where is believed to 
contribute to resistance to chlorhexidine (Poole, 2005). No further 
identification of this gene was made before the start of this thesis. 
These efflux genes are of concern because they are active against biocides 
commonly used in hospitals. They are able to cause resistance to a broad 
range of biocides so the spread of biocides resistance genes could occur 
rapidly (Fraise, 2002b). It has been speculated that these genes could well 
be associated with antibiotic resistance (reviewed by Russell, 2003, Poole, 







Similarity of bacterial biocides and antibiotics resistance 
Bacterial biocides and antibiotics may show similarities in their resistance to 
mechanisms (Russell, 2002, reviewed by Russell, 2003). Nevertheless, there are 
major differences in their mechanisms of bacterial resistance. Enzymatic 
degradation (inactivation), efflux pumps and modification of target sites are 
responsible for the resistance to both antibiotics and biocides (Russell, 2002, 
reviewed by Russell, 2003). A common mechanism of resistance, particularly as a 
first response, for biocides and antibiotics is an efflux pump, with enzymatic 
degradation and target site mutations being less common (Poole, 2002, reviewed 
by Russell, 2003). As the efflux pumps are a common resistance mechanism to 
biocides and antibiotics, they may also be responsible for the cross resistance 
between them. This could result in the inadvertent selection of antibiotic resistant 
mutants during disinfection, potentially causing an outbreak in hospitals (Figure 




Figure 22. Mechanisms of bacterial insusceptibility to biocides and antibiotics 
shows similarities (e.g. permeability barrier, efflux) and differences (e.g. single or 







Aim of this thesis 
 
I. To assess the susceptibility of 64 K. pneumonia isolates against five 
biocides: 1% Chlorhexidine, 1% Benzalkonium chloride, Trigene, 
MediHex-4, Mediscrub; and to 17 antibiotics against 64 isolates of K. 
pneumoniae. 
 
II. To determine the relationship between the reduced susceptibility to 
biocides, the carriage of antiseptic resistance genes, cepA, qacΔE1, qacE 
and antibiotics resistance in K. pneumoniae. 
 
III. To assess the bactericidal activity of five biocides on K. pneumoniae, both 
under ideal conditions and in the presence of organic matter and with the 
association of efflux pump genes that have been linked to antiseptic 













































Bacterial strains  
The standard laboratory strains E. coli NCTC 1048, Pseudomonas aeruginosa 
NCTC 10662, S. aureus NCTC 6571 and Acinetobacter baumannii ATCC 19606 
were used as control strains for the determination of MICs. A. baumannii ATCC 
19606, K. pneumoniae ATTC 13883, K1, K2, Methicillin-resistant 
Staphylococcus aureus MRSA-15 and MRSA-16 were used as control strains for 
cepA, qacΔE1 and qacE antiseptic resistance genes. Sixty-four isolates of K. 
pneumoniae were obtained from Royal Infirmary Hospital in Edinburgh between 
2006 and 2008 from different sites of infection. 
All strains were subcultured on MacConkey agar (Oxoid, Basinstoke, UK) and 
incubated for 18 hours at 37°C. Two to three colonies were inoculated into Iso-
Sensitest (IST)(Oxoid, Basinstoke, UK) broth and incubated overnight at 
37°C/180rpm in an orbital shaker. The next day 900µL of these IST broths of 
overnight shaken culture was added to 100μL sterile glycerol and was stored at -
70°C in a 2mL eppendorf tube for long-term storage at -80°C. The API 20 E strips 
were used for the identification of K. pneumonia according to the manufacturer’s 
instructions of BioMerieux (Basingstoke, UK), Briefly, colonies (between 1 – 4) 
taken from an MacConkey agar plate incubated overnight, were suspended into a 
2mL ampoule of API NaCl 0.85 % medium, the saline suspension was distributed 
into the microtubules and about 5mL of distilled water was distributed into the 
bottom of the tray to create a humid atmosphere. The strip box was incubated at 
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29°C ± 2°C for 24 hours (± 2 hours). After the incubation period, the strip was 
interpreted by referring to the Reference Table.  
 
Media, Buffers and Reagents 
All media were supplied by Oxoid (Basingstoke, UK) in powdered form. The 
broths and agars were dissolved with distilled water and autoclaved at 121°C/15 
pounds per square inch (psi) for 15 minutes according to the manufacturer’s 
instructions. Agar was cooled to 50ºC before being poured into sterile petri dishes 
(Sterilin Ltd, Staffordshire, UK) and allowed to solidify into plates to be used 
immediately or stored at 4ºC. 
All chemicals and buffers were purchased from the Sigma-Aldrich (Poole, UK) 
unless stated otherwise. Normal Saline Solution (NSS), agarose, Tris base and 
MOPS were obtained from Fisher Scientific (Leicestershire, UK). Normal saline 
(0.85%) was prepared by dissolving 0.85g of sodium chloride in 100mL of 







The antibiotic  agents used in this study were purchased from suppliers as sterile 
powders as listed below: Polymyxin B, Cefotaxime, Cefoxitin, Colistin, 
Chloramphenicol, Gentamicin, Rifampicin and Trimethoprim (Sigma, Poole, 
UK), Ceftazidime (GlaxoSmithKline, Brentford, UK), Imipenem (Merck Sharp 
and Dohme, Huddleston, UK) and Meropenem (AstraZeneca, Luton UK). The 
antibiotics were stored in the dark at 4ºC.  
All breakpoints values of antibiotic agents were taken from the British Society for 
Antimicrobial Chemotherapy (BSAC) guidelines for Antimicrobial Susceptibility 
Testing  version 11.1 (Andrews, 2012) with the following exceptions; cefotaxime 
and trimethoprim (> 2mg/L); colistin, polymyxin-B and gentamicin (> 4mg/L); 
ceftazidime, cefoxitin, imipenem, meropenem and chloramphenicol (> 8mg/L) 







The common hospital biocides 1% Chlorhexidine gluconate, a member of 
biguanide family, 1% Benzalkonium chloride and quaternary ammonium 
compounds (QAC) were supplied from Sigma (Poole, UK). The commercial 
biocide preparations Trigene, a mixture of the QAC alkyl dimethyl benzyl 
ammonium chloride and didecyl ammonium chloride, the cationic biocide 
MediHex-4, containing 4% chlorhexidine gluconate and Mediscrub, containing 
1% triclosan were purchased from Medichem International (Kent, UK) (Smith 
and Hunter, 2008).  
 
Antibiotic Discs  
All antibiotic discs were obtained from Mast Laboratories Ltd (Liverpool, UK) at 
the contents listed: amikacin (AK) 30µg, ampicillin (AMP) 25µg, aztreonam 
(ATM) 30µg, carbenicillin (CAR) 100µg, cefotetan (CCT) 30µg, apramycin 
(APR) 15µg, doxycycline (DO) 30µg, netilmicin (NET) 30µg, piperacillin/ 
tazobactam (PRL) 75µg, tigecycline (TCG) 15µg, erythromycin (E) 30µg and 





Minimum Inhibitory Concentrations (MICs)  
A minimum inhibitory concentration is the lowest concentration of the 
antimicrobial agent that completely inhibits growth of bacteria. MICs were 
determined by the agar double dilution agar method, and were carried out using 
Iso-Sensitest (IST) plates containing the particular concentrations of antimicrobial 
agents following the guidelines of BSAC (Andrews, 2006).  
A single colony was suspended in 5mL of IST broth and grown overnight at 37°C 
in an orbital shaker. Antibiotic powders were weighed and dissolved in an 
appropriate solvent according to the BSAC (Andrews, 2006). Water was added to 
ensure that the required concentration of antibiotic stock solution was reached. 
The rest of the antibiotic concentrations were made from this stock solution. The 
bacterial inocula were diluted in 0.85% normal saline solution (NSS) to 
approximately 10
7
 cfu/mL, which is equivalent to a 0.5 McFarland standard 
following BSAC guidelines (Andrews, 2012) by adding 0.5mL of 0.048M BaCl2 
(1.17% w/v BaCl2. 2H2O) to 99.5mL of 0.18M H2SO4. The acceptable absorbance 
range for the standard is 0.08 – 0.13 at 625 nanometre (nm).  
The inocula were always used within the prescribed 30 minute time-frame. An 
A400 multipoint inoculator (Denley, Surrey, UK), was used to inoculate a 1µL 
volume of suspension onto the surface of the agar to give a final inoculum of 
approximately 10
4 
cfu/spot. Plates were allowed to dry and were incubated 
overnight at 35 – 37ºC. The MIC range of antibiotic tested was usually 0.008 – 
128mg/L. A plate without antibiotic was used as a positive control. The positive 
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control plate and the MICs of the standard laboratory strains were used to monitor 
the quality of the tests.  
 
Disc sensitivity testing  
Disc sensitivity testing was complied with the BSAC guidelines (Andrews, 2012). 
Disc sensitivity testing was performed on IST agar, an overnight IST broth culture 
was diluted in 10µL sterile 0.85% normal saline solution (NSS) to match 0.5 
McFarlane as turbidity standard, a sterile cotton swab was dipped into the 
suspension and removal of the excess liquid was made by pressing against the 
side of the test tube, swab the inoculum over the surface of IST agar plate was 
made in three directions. Antibiotic discs have been applied on the surface agar 
plate within 15 minutes of inoculation and the plates were incubated in air at 37°C 
for 18 hours. Disc sensitivity testing was interpreted as sensitive, intermediate or 






Minimum Bactericidal Concentrations (MBCs) 
The minimum bactericidal concentration (MBC) was defined as the lowest 
concentration of the biocide that was able to reduce the viable count by 3 logs10; 
in other words, to kill 99.9% of the original bacteria in a given time or complete 
suppression of bacterial growth (Andrews, 2006, Kawamura-Sato et al., 2008, 
Smith et al., 2008, Smith and Hunter, 2008). The evaluation of basic bactericidal 
activity of five biocides against K. pneumoniae was conducted according to the 
European standard test method EN 1040 guidelines for measuring the reduction in 
the number of bacteria. MBC testing was carried out on Tryptone Soya Agar 
(TSA) (Kawamura-Sato et al., 2008),  
The overnight broth culture was adjusted to an optical density (OD) 0.08 at 
660nm (~ ×10
8
 cfu/mL) in a spectrophotometer (Camspec M330). An overnight 
bacterial suspension (100µL of a 10
8
 cfu/mL suspension) was added to 900µL 
biocides and the mixture was left for exactly 3 minutes at 20 – 22°C. After that, 
100µL of mixture was transferred to 900µL of neutralizer solution which 
consisted of 10% Tween 80, 0.1% histidine and 0.5% sodium thiosulphate from 
Sigma (Poole, UK), 3%lecithin soybean (MP Biomedicals, LLC, Cambridge, UK) 
and Phosphate Buffer Solution (PBS pH 7.4) (Kawamura-Sato et al., 2008), the 
mixture was kept at 22°C for 3 minutes and diluted 1:10 serially with PBS. A 
100µL aliquot of this diluted suspension was spread onto TSA plates and 
incubated at 37°C for 18 hours (Kawamura-Sato et al., 2008).  
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The toxicity of the neutralizer to the bacterial activity was evaluated by adding 
100µL of bacterial suspension to 900µL of neutralizer, the mixture was left for 3 
minutes at 20 – 22°C then 100µL of mixture was spread on TSA plate and 
incubated at 37°C for 18 – 24 hours (Kawamura-Sato et al., 2008).   
 
Assessment of the bactericidal activity of disinfectants 
Time killing test 
Time killing test were performed to assess the bactericidal effects of CHX 
(360mg/L) following the European standard test method EN 1040 (Kawamura-
Sato et al., 2008), the disinfection concentration was lower than the MBC value in 
order to evaluate the bactericidal activity at different exposure times intervals. The 
bacterial cell suspension (100mL) was added to 900mL of disinfectant and 
assayed at 1, 3, 5 and 10 minutes. The number of surviving colonies were counted 







This test assessed bactericidal activity under conditions that simulated the 
presence of organic matter, in this case by using bovine serum albumin (BSA) 
(Roche Diagnostics Ltd., Burgess Hill, UK). The test was performed with CHX 
(360mg/L) using exposure times at 1, 3, 5 and 10 minutes, respectively. However, 
in addition of BSA 1%, 3% and 10% was added to the tubes complying with the 
European standard test method EN 1276 (Kawamura-Sato et al., 2008). The 
samples were assayed by following the same method employed in the time killing 
measurement. 
 
Deoxyribonucleic acid (DNA) extraction  
To extract DNA for PCR reaction, a suspension of 1 to 2 fresh colonies, for each 
isolates, were picked from growth on an overnight MacConkey plate. They were 
mixed with 100μL sterile distilled water in an Eppendorf tubes and the suspension 
was boiled in a waterbath to 100ºC for about 10 minutes to release DNA. 
Eppendorf tubes were centrifuged for 1 minute at 13,000rpm; the supernatant 
containing the bacterial DNA was transferred to new Eppendorf tube and kept at -




The primers used in this study were either from previously published papers or 
were designed using the Primer3Plus software (http://www.bioinformatics.nl/cgi-
bin/primer3plus/primer3plus.cgi). They are listed in Tables 5 and 6 including 
those required to amplify the antiseptic resistance genes cepA, qacΔE1 and qacE. 
They were purchased from Life Technologies Ltd (Paisley, UK). The primers 
were diluted to a concentration of 100pmol/μL according to the manufacturer’s 
guidelines as stock standards. The annealing temperatures are shown in Tables 5 
and 6.  
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Table 5. PCR primers of the antiseptics resistance gene qacE, qacΔE1, sul1 and aadA1 with expecting size of product and the 
annealing temperatures 
 
Gene PCR Primers Product size 
 (bp) 






370  49°C for 40s (Kazama et al., 1998) 
qacΔE1 
sul1 
F 5’ AGGCTGGTGGTTATGCACTC 3’ 
R 5’ CCGACTTCAGCTTTTGAAGG 3’ 
238  56°C for 40s This work 
sul1 
orf5 
F 5’  AGGCTGGTGGTTATGCACTC’3 
R 5’ CGTATAGGCCACGCAGGTT’3 
895  57.5°C for 40s This work 
sul1 
chrA 
F 5’ ACGAGATTGTGCGGTTCTTC’3 
R 5’ GGGGTCATGCTCAACAACTT’3 
974  56°C for 40s This work 
aadA1 
qacΔE1  
F 5’ TGAGGCGCTAAATGAAACCT’3 
R 5’ AACCAGGCAATGGCTGTAAT’3 
1303  56.5°C for 40s This work 
IGR 
aadA1 
F 5’ ATGCCCGTTCCATACAGAAG’3 
R 5’AGGTTTCATTTAGCGCCTCA’3 
1836  56.5 for 40s This work 
dhfrA1 
aadA1 
F 5’ CAATGGGAGCATTACCCAAC ‘3 
R 5’ TACTGCGCTGTACCAAATGC’3 
844   56°C for 40s This work 
qacE F 5’GCCCTACACAAATTGGGAGA3’ 
R 5’TTAGTGGGCACTTGCTTTGG3’ 
350  49°C for 40s (Kazama et al., 1998) 
 
bp, base pair; s, seconds; qac, quaternary ammonium compounds; IGR, intergenic region 
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Table 6. PCR and RT-PCR primers of the antiseptics resistance gene cepA, pfkA, menG, cpxP and cpxP with product size and the 
annealing temperatures 
 
Gene PCR Primer  Product size 
 (bp) 
Annealing temperature References 
cepA F 5’CAACTCCTTCGCCTATCCCG3’ 
R 5’TCAGGTCAGACCAAACGGCG3’ 
1051  66°C for 40 s (Fang et al., 2002) 
cepA 
 pfkA 
F 5’ CGCTGTTCCTGTTTCTCACC3’ 
R 5’ CGCGCTTCTTCATGTTTTC 3’ 
1099  66°C for 40 s This work 
pfkA  
menG 
F 5’ GTTCCTATATGGGGGCGATG 3’ 
R 5’ GAATGGCCGTGGTCATATTC 3’ 
975  63.5°C for 40 s This work 
cpxP 
cepA   
F 5’ CCCCGTTAATGTTAGCGAAA 3’ 
R 5’ CTAACGAGGGCGATCAATGT 3’ 
830  64.5°C for 40 s This work 
cpxR 
cpxP 
F 5’ ATCGAAATTGGCTTCCTGAC 3’ 
R 5’ GGCGTAAGCAGGTGGTACAT 3’ 
830  66°C for 40 s This work 
RT-PCR  
Primer 16S 
F 5’ CAGCCACACTGGAACTGAGA3’ 
R 5’ GTTAGCCGGTGCTTCTTCTG 3’ 
220  66°C for 40 s (Findlay et al., 2012) 
 
bp, base pair; s, seconds; cep, cation efflux pump. 
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Polymerase Chain Reaction (PCR) Reagents and Amplification of 
genes by PCR 
 PCR reactions were run in total volumes of 50μL. The lists PCR reaction 
components (Table 7). The PCR mastermix solution (Promega, Southampton, 
UK) containing (Taq DNA polymerase, dNTPs, MgCl2 and reaction buffers) were 
added into a sterile 0.5mL PCR tube (Fisher Scientific, Leicestershire, UK), 
containing DNA template with primers. 37.8µL sterile distilled water was used as 
the diluent for the reaction and to give a final volume in each tube 50μL (Table 7). 
A negative control contained all the reaction components minus any bacterial 
DNA. 
The PCR tubes were mixed by pulsing in a centrifuge prior to being placed in a 
thermal cycler. PCR cycling was performed in a GeneAmp® PCR System 9700 
thermal cycler (Applied Biosystems, Warrington, UK). Cycling parameters were 
adjusted according to PCR standard protocol as described below in (Table 8). The 
annealing temperatures and numbers of cycles were varied depending on length of 





Table 7. PCR reaction components 
Component Volume (µL) 
 
5×Green or Colorless 
GoTaq® Flexi Buffer1  
 
5.0 
MgCl2 Solution, 25mM  3.0 
 
Go Taq polymerase                           0.2 
 
PCR Nucleotide Mix, 10mM  1.0 
 
Upstream Primer ×25pmol/μL 1.0 
 
Downstream Primer ×25pmol/μL 1.0 
 
DNA template 1.0 
 




Table 8. PCR cycling parameters 
Step Temperature (°C) Time Cycles 
 
Initial Denaturation  94 5 minutes 1 
 




30 – 35 Annealing 55 – 66 40 seconds 
 
Extension 72 50 seconds 
 
Final Extension 72 7 minutes 1 




The constituents of 10×TAE buffer were made in the following order: 48.44g of 
Tris Base, 3.72g of ethylenediaminetetraacetic acid (EDTA) disodium salt 
dihydrate 99%, 11.4mL Glacial Acetic Acid (Biokeystone Co LLC, California, 
USA). The final volume of the buffer was made up to one litre by adding distilled 
water and mixed well until it completely dissolved. The pH of the buffer was 
adjusted to 8.0, sterilized and diluted 1:10 in order to give a final concentration of 
1×TAE ready for use in gel electrophoresis. 
 
Gel electrophoresis of DNA 
The PCR products were separated by agarose gel electrophoresis. 7µL of PCR 
product containing the 5×Green Buffer was loaded directly into 1.5% agarose gel 
GenSieve LE agarose (Flowgen Bioscience, UK) in 1×TAE buffer. The amplified 
PCR containing colorless buffer can be loaded directly into the wells of an 
agarose gel, combined with a 3µL PCR loading buffer Blue/Green dye from 




The agarose was heated in a microwave oven until it dissolved and then left to 
cool at 50ºC. In order to provide a measure of product size, 7µL of DNA ladder 
(comprising either 100base pairs (bp) or 1kilo base (kb)), (Promega, 
Southampton, UK)  as molecular weight markers was loaded with 3µL PCR 
loading buffer Blue/Green dye from Promega (Southampton, UK). The DNA 
ladder and the negative control were run alongside each PCR amplification; the 
DNA ladder was run in the first well of the gel and the negative control in second 
well.  
The gel electrophoresis was performed using the Bio-Rad Mini Sub Cell 
horizontal gel units in 1×TAE buffer at 100 volts in room temperature for 30 – 40 
minutes. Gels were stained in 100mL Red Gel from Biotium (Cambridge, UK) 
according to the manufacturer’s instructions, which consisted of 30µL of Red Gel 
solution diluted with 100mL 0.1M NaCl (11.68g NaCl added to 2 litres of 
distilled water) for 15 – 20 minutes and Gel Red was stored at room temperature. 
Finally, the gel was visualised under a UV light on a UV transilluminator and gel 
image was taken in a Joint Photographic Experts Group (JPEG) with the Diversity 
Database software image capturing system of Bio-Rad GelDoc system (Hemel 





The PCR amplifications were purified with the kit QIAquick PCR Purification 
Kit, which was supplied from QIAGEN Company (West Sussex, UK). The 
purified DNA was stored at -20°C. A clean 5µL of PCR product and 1µL 
sequencing primer forward or reverse (3.2 pmol/µL) was in a total volume of 6µL 
per sample. The nucleic acid sequencing was performed on an ABI 3730 Sanger 
capillary sequencer instrument supplied by Applied Biosystems (Warrington, UK) 
by the Gene Pool (Edinburgh University). The sequences were compared to the 
published sequences of antiseptic resistance genes cepA, qacΔE1 and qacE using 
online databases website of nucleotide blast program of the National Centre for 
Biotechnology Information (http://www.ncbi.nih.gov/BLAST). The Multalin 
website was used for alignment DNA sequence online to observe for any 
differences or changes in the sequences (http://multalin.toulouse.inra.fr/multalin/). 
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Efflux pumps inhibitor and biocides resistance 
The main function of an efflux pump is to excrete of various toxic molecules, 
especially those that are bactericidal, and this mechanism can play an important 
role in bacterial resistance to antibiotics and biocides (Mahamoud et al., 2007). 
Because of this there are several trials to produce chemicals that can be 
administered with antibiotics or biocides to act as efflux pump inhibitors. 
Reserpine, 1-(1-Naphthylmethyl)-piperazine (NMP) and carbonyl cyanide m-
chlorophenylhydrazone (CCCP) (Sigma, Poole, UK) have been used. These can 
inhibit efflux pumps in Gram-negative bacteriaand can be used to determine 
whether an efflux pump was active. 
The efflux pump inhibitors (EPIs) used, such as CCCP,  against biocides 
resistance in K. pneumoniae. A 10mg aliquot of the efflux pump inhibitors (EPIs) 
used, such as CCCP, was dissolved in small volumes of Dimethyl sulfoxide 
(DMSO) (Sigma, Poole, UK) to1 litre of IST agar to make up final concentration 
is 10mg/L and 20mL of molten IST agar, was poured in each plate containing 
increasing concentrations of biocides prepared in a similar manner to that 
previously described earlier for the MIC experiments. Agar plates were inoculated 





Ribonucleic acid (RNA) extraction 
A single colony of each isolate was grown in IST broth to the exponential phase 
an optical density (O.D) of 0.9 – 1.0 at 600 nanometre (nm) (~1×10
9
 cfu). Total 
RNA was extracted from broth culture according to the manufacturer’s 
instructions using the RiboPure Bacteria kit purchased from Ambion (Warrington, 
UK). All equipment and the environment including the benches, gloves and the 
pipettes were decontaminated with TURBO DNase ZAP (Ambion, Warrington, 
UK).  
The eluted RNA was treated with DNA-free DNase (Ambion, Warrington, UK) at 
37°C for 30 minutes to eliminate any traces of contaminating genomic DNA. The 
RNA concentration was measured by loading a 2μL sample onto NanoDrop 
spectrophotometer ND-1000 from Thermo scientific (Cramlington, UK). The 
NanoDrop spectrophotometer was cleaned and blanked with distilled water. The 
average of two independent readings was taken. When it fell between 100 and 
200nanogram (ng), it was deemed to be suitable to be carried forward for cDNA 





Reverse transcription (RT) PCR 
cDNA was synthesized from 100ng of total RNA by reverse transcription 
according to Access RT-PCR System Kit instructions from Promega. A reverse 
transcription (RT) reaction consisted of: 25µL Access Quick™ Master Mix, 
1.5μL upstream and downstream primer, 5μL RNA and 17µL sterilized distilled 
water was used to give a final volume in each tube 50μL into a sterile PCR tube 
(Fisher Scientific, Leicestershire, UK). The RT reaction was mixed thoroughly 
before adding 1μL (5units) AMV Reverse Transcriptase as the final component 
and mixed by gentle vortexing or pipetting (Table 9). The reaction tubes were 
incubated at 45°C for 45 minutes, RT-PCR amplification was run in a 50µL total 
volume for 25 – 30 cycles. 
The RT-PCR amplification product was separated by agarose gel electrophoresis 
in order to assess gene expression and stained with Gel Red. Visualisation, with 
the Bio-Rad GelDoc 2000 software, Quantity One, was used to assess gene 
expression semiquantitatively. The levels of expression RT-PCR products were 
assessed against the 16S gene as negative control of RT-PCR, which was run for 
12 cycles.The intensities of the RT-PCR product bands were normalised and 
compared to the intensities of the 16S bands in order to compare expression levels 




Table 9. Conditions for RT-PCR    
Component  Volume (µL) 
  
Access Quick™ Master Mix, 2X 25 
 
Upstream primer 1.5 
 
Downstream primer 1.5 
 
RNA Template 5 
 
Nuclease-Free Water to a final volume of 50 17 
 




This buffer comprised Tris base (0.089M), and of boric acid (0.089M) and 2.5mM 
disodium EDTA (ICN Biomedical, Aurora, Ohio, USA). The pH was adjusted to 
8.0 and the solution buffer was sterilized. 0.5×TBE buffer was prepared from 




Pulsed-Field Gel Electrophoresis (PFGE)  
Agarose plugs 
PFGE of K. pneumoniae isolates were typed on according to modified protocol 
described by (Miranda et al., 1996). A loopful of fresh bacterial colonies from an 
overnight IST agar plate was inoculated into 3mL of cell suspension buffer 
(100mM Tris Base and 100mM EDTA pH 8.0) and suspended by vortexing, each 
bacterial suspension was adjusted to give a cell density of approximately 10
9 
cells/mL in the spectrophotometer at 610 nm (Camspec M330) using cell 
suspension buffer as the blank.  
 
An aliquot of 25µL proteinase K (20mg/mL) was added to a 500µL cell 
suspension resuspended and incubated at 55°C in a water bath to avoid setting. 
This was followed by adding equal volume of mixture of 1% Certified Megabase 
Agarose, (Bio-Rad, Hertfordshire, UK) and 1% sodium dodecyl sulphate (SDS) 
(Fisher Scientific, Leicestershire, UK) into TE buffer (10mM Tris Base, 1mM 
EDTA, pH 8.0) for the plugs, The mixture was pipetted immediately into the 
wells of plug moulds and allowed to solidify at 4°C for 20 –30 minutes. 
 
A single plug was incubated in 5mL of cell lysis buffer, 50mM of EDTA, 50mM 
Tris Base, 1%N-Lauroyl Sarcosine and 1.0M Sodium chloride at pH 8.0, at 55°C 
in a water bath for two hours. The plugs were washed five times carefully (15 
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min/wash) at 55°C, two times with   sterile distilled water and three times with TE 
buffer  
 
Agarose plug digestion 
For the restriction endonuclease digestion of the genomic DNA, the plug was 
gently sliced into 3 pieces of 4 millimetres (mm) into 100µL of the 1x restriction 
endonuclease buffer (1µL BSA by Promega (Southampton, UK) and 89µL of 
sterilized distilled water) for at least 15 minutes. The restriction buffer was 
replaced with100µL fresh buffer containing 3µL of 30U Xba1 restriction 
endonuclease by Promega (Southampton, UK), 10μL of restriction buffer, 1µL 
BSA and 86μL sterilized distilled water, and tubes were incubated in water bath at 
25°C for overnight. After that the buffer was removed and the reaction was 
stopped by adding 100µL of 0.5×TBE buffer (Miranda et al., 1996).  
 
Gel preparation and running conditions 
The plug slices were loaded into the gel lanes of 1% Pulsed Field Certified 
Agarose (Bio-Rad, Hertfordshire, UK) prepared in 0.5×TBE buffers. A Lambda 
ladder PFGE Marker (New England Biolabs Hertfordshire, UK) was used as the 
size standard marker for PFGE, plugs wells were then overlain with more 1% 
PFGE-grade agarose to seal.  
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Electrophoresis was performed with a CHEF-DRII system (Bio-Rad, 
Hertfordshire, UK). The gel was run for 20 hours at 6.0 volts/cm at 14ºC with 5 
seconds initial pulse time and 45 seconds final pulse time in 0.5×TBE running 
buffer. Gel was stained for 30 minutes in GelRed as described previously, then 
Gel was visualised by UV transillumination on the Bio-Rad GelDoc system 
(Miranda et al., 1996).  
 
Interpretation of PFGE 
All isolates were analysed using BioNumerics software, version 4 (Applied 
Maths, Sint-Martins-Latem, Belgium). Isolates which clustered together with a 
similarity of > 85% were considered to belong to the same PFGE type. Results 
were obtained as phylogenetic trees. A value of 80% was selected as the threshold 
for the establishment of clonal relatedness of unknown isolates. The banding 
























MICs of biocides and antibiotics against the Klebsiella strains 
MICs of biocides 
The susceptibility of the 64 Klebsiella isolates was determined by measuring the 
MIC of antibiotics and biocides. The ranges of MIC for each biocide are shown in 
(Table 10 and Figure 23). There was a decrease in susceptibility to the 
disinfectants 1% Chlorhexidine gluconate (CHX), 1% Benzalkonium chloride 
(BZK) and the commercial biocide Trigene with MICs ranging from 32 – 
128mg/L. This is considered as high level of insusceptibility, it should be noted 
that 57, 55 and 61 isolates had reduced susceptibility to Chlorhexidine, Trigene 
and Benzalkonium chloride, respectively, and the high of resistance was verified 
by the high MIC50 as well as MIC90 values (Table 10).  
The cationic biocide Medihex-4 (MH-4), containing 4% chlorhexidine. Strains 
showed a moderate level of MICs to MH-4 from 8 – 16mg/L in 58 isolates; these 
were approximately 4-fold lower than Chlorhexidine reflecting the 4-fold increase 
in chlorhexidine concentration in this commercial product (Table 10 and Figure 
23). On the other hand, 63 isolates were susceptible to Mediscrub (MS), 
containing 1% triclosan with MICs ≤ 4mg/L, though the remaining one was far 
less susceptible (MICs > 128mg/L)  (Table 10 and Figure 23), again was verified 
by the MIC50 and MIC90 values (Table 10) 
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The results show four of the biocides had MIC ranges starting at greater than 
1mg/L, with two of them having the lowest MIC at 16mg/L. The exception to this 
was Mediscrub, which had an MIC range beginning at 0.12mg/L and extending 
only to 0.5mg/L. Chlorhexidine, Benzalkonium chloride and Trigene had identical 
MIC50 and MIC90 values; whereas Medihex was about four-fold lower. In stark 
contrast Mediscrub had much lower MIC50 and MIC90 values (Table 10). This 
means that the MIC50 of Chlorhexidine, Benzalkonium chloride and Trigene was 
at least 256-fold higher than the MIC50 of Mediscrub. The MIC details of all 
biocides are shown in appendix A.  
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Table 10.  The MIC summary of biocide and the ranges of MIC50 and MIC90 of biocides against 64 K. pneumoniae isolates 
 
Biocides 









0.12 0.25 0.5 1 2 4 8 16 32 64 128 
 
CHX - - - - - 1 1 5 34 20 3 4 – 128 32 64 
 
Trigene - - - - - - - 9 41 14 - 16 – 64 32 64 
 
MH-4 - - - - 1 5 45 13 - - - 2 – 16 8 16 
 
MS 45 6 12 - - - - - - - 1 0.12 – 128 0.12 0.5 
 
BZK - - - - - - - 3 48 13 - 16 – 64 32 64 
 
 
CHX, Chlorhexidine; MH-4, MediHex-4; MS, Mediscrub; BZK, Benzalkonium chloride.
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Figure 23. Distribution of MICs of biocides among 64 K. pneumoniae isolates, All biocides range started from 2mg/L to >128mg/L 
of MIC, except Mediscrub antiseptic begun from 0.12mg/L to 0.5mg/L of MIC.          
CHX, Chlorhexidine; MH-4, MediHex-4; MS, Mediscrub; BZK, Benzalkonium chloride. 
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MICs of antibiotics 
Number of isolates were resistant to the antibiotics tested particularly some of the 
β-lactams and the MICs of the antibiotics for 64 isolates are shown in (Table 11 
and Figure 24). 3
rd
 generation cephalosporins, colistin, gentamicin, polymyxin-B, 
trimethoprim and chloramphenicol antibiotics were resistance to 17, 34, 3, 1, 12, 
and 4 isolates respectively (Table 11 and Figure 24); however all K. pneumoniae 
isolates were sensitive to imipenem (MIC  2mg/L) and meropenem (MIC  
0.12mg/L) (Table 11).  The population was resistant to rifampicin with 49 isolates 
having MICs above the breakpoint; this was confirmed by the high MIC50 value 
(Table 11).   
Out of the 64 K. pneumoniae isolates, 8 were resistant ceftazidime, 9 were 
resistant to cefotaxime and 17 were resistant to cefoxitin. Thirty-four were 
resistant to colistin, however most of isolates were susceptible to polymyxin-B 
antibiotic with the exception that one isolate was resistant to it, again supported by 
the MIC50 values (Table 11 and Figure 24). The ranges of MICs and the variations 
in MIC50 values of cephalosporins, colistin, gentamicin, trimethoprim and 
chloramphenicol varied widely, the MIC50 values spanned from 0.06 to 8mg/L. In 
general the level of resistance to the biocides was considerably greater than to the 
antibiotics (Table 11). The susceptibility details of all antibiotics are demonstrated 
in appendix A.  
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Table 11. The summary of MIC of antibiotics and the ranges of MIC50 and MIC90 values of antibiotics against 64 K. pneumoniae 
isolates 
 
Breakpoint; cefotaxime and trimethoprim (> 2mg/L); colistin, polymyxin-B and gentamicin (> 4mg/L); ceftazidime, cefoxitin, 




Number of strains at each MIC (mg/L) of Antibiotics 





(mg/L) 0.015 0.03 0.6 0.12 0.25 0.5 1 2 4 8 16 32 64 128 
 
Cefotaxime  14 22 13 2 5 - - - - - 1  7 0.03 – 128 0.06 128 
Ceftazidime - - - 8 27 12 8 - - - -  4 5 0.12 – 128 0.25 64 
Cefoxitin - - - - - - - 1 20 26 10 3 2 2 2 – 128 8 32 
Imipenem - - - 15 28 11 10 - - - - - - - 0.12 – 1 0.25 1 
Meropenem 43 19 2 - - - - - - - - - - - 0.015-0.06 0.015 0.03 
Colistin - - - - - - - 1 29 34 - - - - 2 – 8 8 8 
Rifampicin - - - - - - - - - 1 14 33 16 - 8 – 64 32 64 
Gentamicin - - - 3 37 18 2 - 1 - - - 3 - 0.12 – 64 0.25 0.5 
Polymyxin B - - - - - 1 58 3 1 1 - - - - 0.5 – 8 1 1 
Trimethoprim - - - 1 6 43 1 1 - 3 1 - - 8 0.12 – 128 0.5 128 
Chloramphenicol - - - - - - - - 42 16 2 - - 4 4 – 128 4 8 
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Figure 24. Distribution of antibiotics MICs for the 64 clinical K. pneumoniae isolates. 
CTX, Cefotaxime; CTZ, Ceftazidime; CXT, Cefoxitin; IMP, Imipenem; MEM, Meropenem; COL, Colistin; RIF, Rifampicin; GEN, 
Gentamicin; Poly-B, Polymyxin B; TRI, Trimethoprim; CHL, Chloramphenicol.
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Disc diffusion test 
Further antibiotics were tested by the disc sensitivity test. All isolates were 
sensitive to Amikacin (AK), Apramycin (APR) and Cefotetan (CCT) antibiotics, 
but some isolates were resistant to some antibiotics (Table 12). K. pneumoniae 
isolates were resistant mainly to penicillin antibiotic, and the most of isolates (62) 
were insusceptible to ampicillin (AMP); followed carbenicillin and doxycycline 
antibiotics with 44 and 39 isolates insusceptible respectively, whereas 26 isolates 
were resistant to piperacillin. However, one isolate was resistant to netilmicin and 
tigecycline antibiotics individually (Table 12 and Figure 25).  
Table 12. The number of K. pneumoniae isolates resistant to antibiotics 





Antibiotic discs (µg) Number of isolates resistant 
 
Ampicillin (25) 62 
 
Carbenicillin (100) 44 
 
Doxycycline (30) 39 
 
Piperacillin (75) 26 
 
Erythromycin (30) 7 
 
Novobiocin (30) 4 
 
Aztreonam (30) 2 
 
Netilmicin (30)               1 
 




Figure 25. Distribution of antibiotic susceptibility test discs for 64 K. pneumoniae 
AMP, Ampicillin;  ATM, Aztreonam;  CAR, Carbenicillin;  APR, Apramycin;  
DO, Doxycycline; NET, Netilmicin;  PRL, Piperacillin; TCG, Tigecycline; E, 
Erythromycin; NV, Novobiocin. 
 









Antiseptics resistance genes  
In order to determine whether the decreased susceptibility could be correlated 
with specific resistance genes, PCR was used to amplify the antiseptic resistance 
genes qacE and qacΔE1, these genes have been associated as playing an 
important role in decreasing susceptibility to antiseptics (reviewed by Russell, 
2003).  The cation efflux pump associated with chlorhexidine resistance gene, 
cepA, was described on only one occasion before (Fang et al, 2002) and the 
presence of this gene was also sought by PCR. The antiseptics resistance genes 
cepA, qacΔE1 and qacE PCRs were performed with primers described earlier 
(Tables 5 and 6).   
The primers pairs of Fang et al (2002) were used to identify the cepA gene. These 
primer pairs were used to amplify a 1051 base pair (bp) product with an annealing 
temperature 66ºC for 30s (Table 6) (Fang et al., 2002). In 56 isolates a gene 
fragment of 1051 base pairs was found with these primers indicating the presence 
of the cepA gene (Figure 26). The association between antiseptic resistance gene 












































































































































































































































                                                                          
 
Figure 26. An agarose gel showing PCR amplification of cepA gene  for 64 
isolates  of K. pneumoniae , A 100bp marker  in lane 1, A negative control in lane 
2, positive controls K. pneumoniae ATTC 13883  and K1 in lanes 3 and 4 
respectively, and K2 in lane 5 (as negative control) .  
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The quaternary ammonium compound resistance genes qacΔE1 and qacE were 
amplified according to primer pairs designed by Kazama et al (1998). The primer 
pairs of qacΔE1 and qacE genes were used to amplify 370 and 350 bp fragments 
respectively, each having the same annealing temperature 49ºC for 40s (Table 5) 
(Kazama et al., 1998).  
The qacΔE1and qacE genes were amplified by PCR, the qacΔE1 gene was 
detected in 34 isolates, while qacE was found in only one isolate (detailed in 
appendix A), and PCR amplification of qacΔE1and qacE genes are shown in 
(Figures 27 and 28). The linkage between the presence of the qacΔE1 and qacE 



































































































































































































































Figure 27. An agarose gel showing PCR amplification of qacΔE1 gene for 64 
isolates of K. pneumoniae ,  100bp or 1kb  markers in lane 1, A negative control 
in lane 2, A positive control A. baumannii ATCC 19606 in lane 3, and  K. 
pneumoniae ATTC 13883, K1 and K2 in lanes 4, 5 and 6 respectively (as negative 
control). 
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Figure 28. An agarose gel showing PCR amplification of qacE gene for 14 of 64 
isolates of K. pneumoniae,  A 1kb markers in lane 1, A negative control in lane 2, 
A positive control A. baumannii ATCC 19606 in lane 3,   and K. pneumoniae 
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Table 13 associates the individual levels of Chlorhexidine, Trigene and 
Benzalkonium chloride susceptibility with the presence of the individual 
antiseptic resistance genes cepA, qacΔE1 and qacE. Medihex-4 was not tested as 
its main component is 4% chlorhexidine and the strains were susceptible to 
Mediscrub so this biocide was not included either. High level resistance (MICs 32 
– 128mg/L) of Chlorhexidine, Trigene and Benzalkonium chloride was found in 
50, 49 and 53 isolates respectively; in each case the cepA gene was present, while 
qacΔE1 and qacE antiseptics resistance genes were found in 31, 33 and 34 
isolates for Chlorhexidine, Trigene and Benzalkonium chloride respectively. 
Every isolate that had an MIC of Trigene or Benzalkonium chloride (both 
containing quaternary ammonium compounds) ≥ 16mg/L possessed either the 
qacE or qacΔE1 gene (Table 13). Thirty-two isolates had both cepA and qacΔE1 
genes, whereas just one isolate has both cepA and qacE gene and six isolates had 
no efflux pumps genes (Table 13).  
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Table 13. Association of individual MICs of Chlorhexidine, Trigene and Benzalkonium chloride with the presence of the cepA, 






Antiseptics Resistance Genes 
 







Chlorhexidine 4 1      1 
8 1 1      
16 5 5 4   4 1 
32 34 28 20   19 4 
64 20 19 9 1 1 8  
128 3 3 1   1  
Trigene 16 9 7 1 1 1 1 2 
32 41 39 24   24 2 
64 14 10 9   7 2 
Benzalkonium 
chloride 
16 3 3 1   1  
32 48 43 27 1 1 25 3 
64 13 10 6   6 3 
 
qac, quaternary ammonium compounds; cep, cation efflux pump. 
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Efflux pump inhibitor and biocides resistance 
The main function of efflux pump is to pump out various metabolites, usually 
those that are detrimental to the cell. This mechanism can play an important in 
bacterial resistance to antibiotics and biocides (Mahamoud et al., 2007). 
Consequently, there are several compounds that can be administered with 
antibiotics or biocides to act as efflux pump inhibitors (EPIs). Reserpine, 1-(1-
Naphthylmethyl)-piperazine (NMP) and carbonyl cyanide m-
chlorophenylhydrazone (CCCP) can inhibit efflux pumps in Gram-negative 
bacteria (Garvey and Piddock, 2008). 
The phenotypic effect of efflux pumps on biocides was determined by repeating 
the susceptibility tests in the presence of the EPIs. There was no impact of the 
EPIs reserpine and 1-(1-Naphthylmethyl)-piperazine (NMP) on the susceptibility 
of the five biocides. The presence of the EPI CCCP (10mg/L), on the other hand, 
provided a different response when it was examined on the MICs of the biocides. 
Although, it had no impact on Benzalkonium chloride, Trigene and Mediscrub 
(data not shown), it reduced the MICs of Chlorhexidine and Medihex-4 by 
between 2 and 128-fold (Table 14). In the case of Chlorhexidine, this was 
associated, except in 5 cases, with the presence of the cepA gene. The presence of 
CCCP had slightly less effect on Medihex-4 and this was associated, except in 8 
cases, with the presence of the cepA gene. The qacΔE1 gene was associated with 
less than half of the strains showing the reduction of Chlorhexidine and Medihex-
4 MICs indicating that this gene does not play a role in biguanide susceptibility. 
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CHX, Chlorhexidine, MH-4, Medihex-4  
No of 
strains 
Fold reduction  




1 8 - - 
1 8 + - 
3 8 + + 
1 16 - - 
3 16 + - 
3 16 + + 
11 32 + - 
2 32 - + 
15 32 + + 
1 64 - - 
7 64 + - 
9 64 + + 
2 128 + - 








1 2 + + 
2 4 - - 
4 4 + - 
1 8 - - 
1 8 - + 
6 8 + + 
2 16 - - 
1 16 - + 
11 16 + - 
21 16 + + 
1 32 - - 
7 32 + - 
5 32 + + 
1 64 + + 
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Minimum Bactericidal Concentrations of biocides 
Minimum bactericidal concentration (MBC) value is defined as the lowest 
concentration that reduced the bacterial count by at least 99% inhibition. The 
MBC value was identified using the European standard test method EN 1040 
quantitative suspension test described above.  
Six isolates of K. pneumoniae isolated were chosen for their varying sensitivity to 
Chlorhexidine in appendix A, MBCs were calculated for the six isolates using the 
differences between the proportion of surviving colonies and a control (bacterial 
suspension was treated with PBS only). The 6 isolates of K. pneumoniae were 
tested against five biocides for assessment their MBCs. In this test, MBCs of the 
active component of five antibacterial disinfectants were measured, as stated by 
the manufacturer and the results are shown in Table 15.  
The MBC of Trigene was the same for all strains at 1800mg/L of the active 
component (polymeric biguanide hydrochloride). The MBCs of Chlorhexidine 
ranged from < 360mg/L to 900mg/L, whereas those for MediHex-4, between 
< 36mg/L to 360mg/L, and Benzalkonium chloride, at 90mg/L, were lower. The 
MBC for Mediscrub was the highest for each strain at 9000mg/L. The presence of 




Table 15. The Minimum Bactericidal Concentration (mg/L) expressed as the 
minimum concentration required to reduce the viable count of bacteria by 
100-fold in 3 minutes according to the method of Kawamura-Sato et al. (2008). 
Strain Minimum Bactericidal Concentration (mg/L) Efflux genes 
CHX Trigene MH-4 MS BZK  cepA qacΔE1 
14 < 360 1800 < 36 9000 90 - - 
16 < 360 1800 < 36 9000 90 + - 
24 900 1800 360 9000 90 + + 
37 900 1800 360 9000 90 + - 
52 < 360 1800 < 36 9000 90 + - 
64 < 360 1800 < 36 9000 90 + + 
 
CHX, Chlorhexidine; MH-4, MediHex-4; MS, Mediscrub; BZK, Benzalkonium 
chloride. 
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The highest ratio of MBC/MIC was Mediscrub with ratio number between 
>18000 and > 75000, followed by Trigene has a ratio between >112 and >28, 
although Chlorhexidine, MediHex-4 and BZK, Benzalkonium chloride have a 
ratio range between 2 to 7 with  4 of 6 strains. 
Table 16. Ratio of MBC/MIC of biocides against K. pneumoniae. 
This is the ratio of the MBCs, determined in Table 15, divided by the MICs for 
the same six isolates, listed in Appendix A.  
Strain Ratio 
CHX Trigene  MH-4 MS BZK 
14 90 > 112 4 > 75000 3 
16 45 > 56 4 > 18000 2 
24 7 > 28 45 > 18000 3 
37 7 > 56 45 > 75000 3 
52 3 > 28 2 > 18000 2 
64 6 > 28 2 > 70 3 
 





Assessment of bactericidal activity of disinfectants 
Time killing test 
The bactericidal activity was evaluated by time-killing assays, Time killing test 
were performed to assess the bactericidal effects of Chlorhexidine following the 
European standard test method EN 1040, with assay times of 1, 3, 5 and 10 
minutes (Kawamura-Sato et al., 2008).  
Chlorhexidine is the active component of many proprietary antiseptics. The 
activity of Chlorhexidine was measured at 40% of the lowest determined figure 
for the MBC (360mg/L), in order to obtain a drop in viability that could be 
precisely measured. The time for bacterial complete killing after exposure to 
360mg/L of Chlorhexidine was 10 minutes to reduce the viable count of bacteria 
by three logarithms10. This concentration of Chlorhexidine has the ability to 
reduce the viability of both K. pneumoniae strains 24 and 37 within 10 minutes 




This test was evaluated bactericidal activity, under conditions that simulated the 
presence of organic matter, in this case by using bovine serum albumin (BSA). 
The isolates were examined against Chlorhexidine at 360mg/L in presence of 
BSA 1%, 3% and 10% complying with the European standard test method EN 
1276. 
The six isolates were examined against Chlorhexidine at 40% of the lowest 
determined figure for the MBC (360mg/L) in the presence of BSA 1%, 3% and 
10%, The effect of Chlorhexidine was almost eliminated for strain 24 once the 
concentration of BSA had reached 10% (Figure 29), the effect was considerably 
less in strain 37 (Figure 30). In general, as the concentration of BSA was 
increased, the ability of Chlorhexidine to kill the bacteria was reduced, BSA 
decreased the MBC value of Chlorhexidine and the rate of survival colonies was 
raised particularly with 10% BSA (Figures 29 and 30).  In contrast, 10% BSA had 




Figure 29. The effect of time on the bactericidal effect of Chlorhexidine 
(360mg/L) against K. pneumoniae strain 24 and the impact of increasing 
























The viability of strain 24 was monitored against time in the presence of 
Chlorhexidine at 40% of the MBC (♦). The experiment was repeated in the 






Figure 30. The effect of time on the bactericidal effect of Chlorhexidine 
(360mg/L) against K. pneumoniae strain 37 and the impact of increasing 
























The viability of strain 37 was monitored against time in the presence of 
Chlorhexidine at 40% of the MBC (♦). The experiment was repeated in the 







Genetic environment of the cepA antiseptic resistance gene  
 The cepA gene was amplified by PCR in 56 isolates (Figure 26). In 45 of these 
isolates we have now identified the 6-phosphofructokinase-1 (pfkA) downstream 
of cepA gene. In 40 of these isolates the methyltransferase gene (menG) was 
directly downstream of the pfkA gene (Figure 31). The periplasmic repressor gene 
(cpxP) was identified upstream of cepA in 47 isolates. The transcription regulator 
(cpxR) was directly upstream of the cpxP gene in 35 of these isolates (Figure 31).  
    
   
 
            cpxR cpxP cepA pfkA          menG  
 
Figure 31. Schematic representation of the genetic environment of the antiseptic 







Reverse transcription (RT) PCR  
RT-PCR analysis of the cepA gene showed that it was expressed particularly in 
those strains with high MICs of Chlorhexidine (Figure 32 and Table 17). When 
these results were plotted against the log10 of the MIC, there was a correlation 
between the degree of expression and the MIC indicating that cepA contributed to 
active efflux mechanisms (Figure 33).  
                                         
 
 
Figure 32. RT-PCR demonstrated the expression of isolates carried cepA11, 16, 
24,26,34,37 and 52, A 1kb DNA ladder with the DNA band sizes (bp) are noted 
on the left in lane 1, and a negative control in lane 2. 
 
 1kb    -ve    7      11     14    16      17     24     26     34     37    39     52    55 
 










Table 17. RT-PCR showing the expression level of the cepA gene in strains 
especially with high level MICs of Chlorhexidine 
 
Isolates MIC of Chlorhexidine 
(mg/L) 
cepA carriage Level of Expression  
(Arbitrary units) 
 
16S control - - 100 
7 32 - 108 
11 32 + 142 
14 4 - 114 
16 8 + 119 
17 64 - 107 
24 128 + 147 
26 32 + 137 
34 32 + 169 
37 128 + 174 
39 32 - 106 
52 128 + 222 




















    
 








1 10 100 1000
MIC of Chlorhexidine (mg/L) 
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Genetic environment of the qacΔE1 antiseptic resistance gene 
The qacΔE1 gene was amplified by PCR in 34 isolates (Figure 27). The 
sul1sulfonamide resistance gene was detected directly downstream of the qacΔE1 
gene in 4 of 34 isolates (Figure 34 and 35). An open reading frame with no known 
function (orf5) was detected directly downstream of the sul1 gene in two isolates 
11 and 17 (Figure 34 and 37); however isolate number 26 had the chromate 
resistance protein gene (chrA) downstream of the sul1 gene (Figure 34 and 39). 
The alignment sequences of the nucleotides of downstream qacΔE1gene (sul1, 
orf5 and chrA are shown in Figures 36, 38 and 40 respectively. 
The aminoglycoside adenyltransferase gene (aadA1), was found directly upstream 
of qacΔE1 in 4 of 34 isolates possessing this gene (Figure 34 and 41), further 
analysis revealed that three of these isolates (11, 17 and 26) had the dihydrofolate 
reductase dhfrA1 gene directly upstream of aadA1(Figure 34 and 43). Two of 
these isolates (11 and 17) had an intergenic region (IGR) between the aadA1 and 
the qacΔE1 genes, which was lacking in the other two isolates (26 and 34) (Figure 
34 and 45). The nucleotide sequence alignments of the region upstream of 
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Figure 35. PCR amplification of four isolates of K. pneumoniae (11, 17 26 and 
34) which carried the qac∆E1sul1 genes, A 1 kilo base DNA ladder in lane 1, A 







     1kb       –ve      +ve      11       17        20        26       34  
 











Figure 36. The alignment of nucleotide sequences of qac∆E1sul1 genes from 
four isolates of K. pneumoniae (11, 17 26 and 34).  
The red coloured letters indicate nucleotide sharing consensus. The blue colured 
letters indicate low consensus areas. 
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Figure 37. PCR amplification of two isolates K. pneumoniae (11 and 17) has 
sul1orf5 genes, A 1kb DNA ladder is in lane 1, The negative control is in lane2.  
 
Figure 38. The nucleotide sequence alignments of sul1orf5 genes from two 
isolates K. pneumoniae (11 and 17). 
 1kb    –ve      11     17    
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Figure 39. PCR amplification of isolates number 26 K. pneumoniae carried 
sul1chrA genes, A ladder 1kb marker is in lane 1, A negative control is in lane 
2. 
   
Figure 40. The nucleotide sequence of sul1chrA genes from isolates number 26 
K. pneumoniae aligned with K. pneumoniae EF21934.4. 
 1 kb    -ve       26 
 











    
 
 
Figure 41.  PCR amplification of four isolates of K. pneumoniae (11, 17, 26 and 
39) are shown aadA1qac∆E1genes, A 1kb DNA ladder is in lane 1, A negative 
control is in lane 2. 
 
Figure 42. The alignment nucleotide sequences of aadA1qac∆E1genes from 
four isolates of K. pneumoniae (11, 17, 26 and 39).  
 1kb    -ve  2    11   17    20   26  39    46   60 
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Figure 43. PCR amplification of three isolates of K. pneumoniae (11, 17and 26) 
showing the dhfrA1aadA1 genes, A ladder 1kb marker is in lane 1, A negative 
control is in lane 2. 
 
Figure 44. The nucleotide sequence alignments of dhfrA1aadA1 genes from of 
three isolates of K. pneumoniae (11, 17and 26).  
 1kb     -ve    11      17      26      34      39      60 
 











      
 
 
Figure 45. PCR amplification of two isolates of K. pneumoniae (11 and 17) which 
have an Intergenic region aadA1, A 1kb DNA ladder isin lane 1, A negative 
control is in lane 2. 
 
Figure 46. The alignment of nucleotide sequences of Intergenic region 
aadA1genes from two isolates of K. pneumoniae (11 and 17).  
1kb     -ve   2    11    17      20    26     39    46    60  
 











When examined by PFGE, isolates 26 and 39 showed virtually identical patterns 
(> 95%), suggesting that they are the same strain; whereas, isolates 11 and 34 
demonstrated similar, but not identical, band patterns (80%) indicating that they 




   
 
Figure 47. The pulsed-field typing of strains 11,17,26,34 and 39 after digestion 
with XbaI.  
 
 Lambda Ladder   11      17      26      34      39 
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The increasing incidence of K. pneumoniae infectious in hospitals worldwide has 
led to a greater awareness of the hazards of nosocomial infections and resulted in 
increased infection control measures. 
Biocides are currently considered to be an essential component of infection 
control strategies in hospitals (Smith et al., 2008), and there is very little in the 
published literature about the effects of chlorhexidine and other antiseptics on 
clinical strains of K. pneumoniae. Block and Furman (2002) have observed a 
significant inverse relationship between the intensity of chlorhexidine use and the 
overall susceptibility of organisms (S. aureus, coagulase-negative staphylococci, 
K. pneumoniae, P. aeruginosa, A. baumannii and Candida albicans to this 
antiseptic (Block and Furman, 2002, Smith et al., 2008).  Furthermore, Koljalg et 
al (2002) found good correlation between chlorhexidine and antibiotic 
susceptibility in 70 distinct clinical isolates. They studied MBCs and MICs of 
small numbers of E. coli, K. pneumoniae, P. aeruginosa, A. baumannii, S. aureus 
(not MRSA), Streptococcus pyogenes and Enterococcus faecalis. They noted that 
non-fermentative Gram-negative bacteria tolerated chlorhexidine at high 
concentrations better than the Enterobactericeae and that Gram-positive cocci, 




The efficacy of five biocides, used extensively in hospitals, was screened against 
64 clinical isolates of K. pneumoniae. The disinfectants showed susceptibility to 
Mediscrub except strain 64, the MIC being determined to the concentration of 
polymeric biguanide hydrochloride (triclosan). Mediscrub was the most effective 
biocide against K. pneumoniae compared with the others tested, with MICs 
between 0.12 and 0.5mg/L Mediscrub is used for washing hands and the 
surfactants, present to reduce the surface tension, clearly are also have an effect 
on the viability of the bacterial cells.  
The main component of Medihex-4 is chlorhexidine gluconate and it was the MIC 
of this compound that was measured; however, the MICs of Medihex-4 were 
lower than that of the Chlorhexidine preparation. Medihex-4 also contains 
cocamidopropyl betaine and sodium lauryl sulphate as surfactants and these may 
also contribute to the reduced MICs found with this preparation. On the other 
hand, Benzalkonium chloride and Trigene were the least effective, the activity 
was also boosted by the surfactant sodium lauryl sulphate. The strains were less 
sensitive to Trigene, which also has polymeric biguanide hydrochloride as a main 
active component. Again the MICs were determined to the concentration of 





The MICs of the polymeric biguanide hydrochloride antiseptics, Mediscrub and 
Trigene, were much lower than the MBCs, in some cases by 10,000-fold. The 
MBC of Mediscrub and Trigene was 9000mg/L and 1800mg/L respectively, 500-
fold greater than the minimum inhibitory concentration (MIC); this strongly 
indicates that these antiseptics are mainly primarily bacteriostatic in their action 
against K. pneumoniae and to obtain a rapid kill, large quantities would have to be 
used. This suggests that in clinical concentrations they have little capacity to 
eradicate K. pneumoniae. Although the MIC of Benzalkonium chloride was high, 
the MBC was not much higher indicating that one the concentration threshold of 
inhibiting the bacterium had been reached, a three-fold increase was sufficient to 
kill the bacteria quickly. 
On the other hand, the MBCs of Chlorhexidine and MediHex-4, which contains 
chlorhexidine, were < 360mg/L and < 36mg/L correspondingly, the differential 
between the MICs and the MBCs of the two chlorhexidine compounds was low 
and a 5-fold increase above the MICs of chlorhexidine was sufficient to elicit a 
rapid bactericidal response, which would be important in clinical practice.  
The presence of organic matter, represented here by Bovine serum albumin, 
suggests that Chlorhexidine is very sensitive to its presence though the extent of 
this will vary from strain to strain. In order of that clinical isolates of K. 
pneumoniae may not respond to common biocides, which may not kill the 




The presence of the qacΔE1 and cepA genes is considered to be linked to high 
level MICs of biocides, the genetic environment of the two major antiseptic 
resistance genes, qacΔE1 and cepA, in K. pneumoniae. About half of the isolates 
carried the qacΔE1 gene and this was usually located upstream of the sul1 
sulphonamide resistance gene and directly downstream of the aminoglycoside 
adenyltransferase gene (aadA1), which was flanked by the dihydrofolate 
reductase gene dhfrA1. 
The qacΔE1 gene appears to be part of a small resistance island suggesting that 
this gene is linked and migrates with antibiotic resistance genes. The close linkage 
of qac genes to antibiotic resistance genes has been identified before in resistance 
island. In the largest resistance island reported to date, in A. baumanii strain AYE, 
there are four qac genes in the 45 gene resistance island (Fournier et al., 2006),
 
suggesting that there is strong selective pressure for these genes. The widespread 
carriage of qac genes in K. pneumoniae, and their linkage to antibiotic resistance 
genes suggests that widespread use of biocides, particularly as antiseptics, could 







The cepA gene was much more prevalent than the qacΔE1, it was present in 88% 
of the isolates. This gene has only once been associated with chlorhexidine 
resistance (Fang et al., 2002). In many isolates, downstream of cepA, there was a 
gene encoding 6-phosphofructokinase-1 (pfkA) and often a methyltransferase 
gene (menG) beyond that. More interestingly, in many of these isolates, the cepA 
gene was located behind cpxR/cpxP transcription regulator genes and these are 
responsible for the gene expression. 
The results show that as the MIC increases so does the expression of cepA. The 
almost universal carriage of the cepA gene in K. pneumoniae and, as this study 
indicates, the expression of which is linked to the Chlorhexidine MIC indicates 
that much of the K. pneumoniae population carries the potential for resistance. If 
biocides are used as recommended, the concentration of the biocide should far 
exceed the MIC of even the resistant strains. However, many biocides are not 
used appropriately and this will select out resistant strains, as indicated by the 








The MIC assays performed in the presence of efflux pump inhibitor (EPI) cyanide 
m-chlorophenyl hydrazone (CCCP), showed that there was a considerable 
decrease in the Chlorhexidine MICs for almost all the strains and this was usually 
associated with the presence of cepA. On the other hand, there were reductions of 
the MediHex-4 MICs, but these were not as great as with Chlorhexidine, and not 
significantly associated with the presence of either the cepA or qac genes.  
This suggests that efflux pumps, as yet undefined, are capable of exporting 
MediHex-4 but this does not play an important role in MediHex-4 susceptibility in 
these Klebsiella strains. The lack of influence of CCCP on the MICs of 
Benzalkonium chloride, Trigene and Mediscrub suggest that other resistance 
genes are more important, particularly for Benzalkonium chloride and Trigene. It 
was interesting to note though that for both these antiseptics there was a high 









It is interesting to note that the proportion of reduced biocide susceptibility was 
high and the carriage of biocide resistance genes was also high. This suggests that 
the Klebsiella population in the Infirmary has been exposed to a considerable 
quantity of biocides and that reduced susceptibility is creeping into the population. 
However, the clinical importance of this may be doubtful as the concentration of 
biocides used is usually far greater than the MICs, even of the strains with 
reduced susceptibility.  
This is likely to be become more important when other factors are taken into 
account, such as biofilm formation, which already compromise the activity of the 
biocide (Smith and Hunter, 2008,Tumah, 2009). Furthermore, this population was 
not noticeably resistant to the antibiotics tested and these results are in contrast 
with those of Koljalg et al.; however, in that study only a very small proportion of 
the strains tested were Klebsiella spp. (Koljalg et al., 2002). There is evidence in 
other species that biocide resistance genes can be closely linked to antibiotic 
resistance genes and, if that occurs in this species in the future, the use of biocides 
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1 32 32 8 0.12 32 0.12 0.25 16 0.12 0.015 4 64 0.5 1 0.5 8 AMP,CAR, 
E, DO, PRL 
+ + 
2 64 32 16 0.12 32 0.06 0.25 8 0.5 0.015 8 64 0.5 1 0.5 4 AMP, DO + - 
3 32 32 8 0.12 32 0.03 0.12 8 0.25 0.015 8 32 0.25 1 0.5 4 AMP,CAR, 
PRL 
+ + 
4 32 32 8 0.12 64 0.12 0.25 4 0.25 0.015 8 16 0.5 1 0.5 4 AMP,CAR, 
DO 
+ + 
5 32 32 8 0.12 32 0.03 0.25 4 0.12 0.015 8 16 0.25 1 0.5 4 AMP,CAR, 
DO 
+ + 
6 64 32 8 0.12 32 0.03 0.5 8 1 0.015 8 64 0.25 1 0.5 8 AMP, DO + - 
7 32 16 2 0.12 32 0.06 0.25 4 0.25 0.03 8 64 0.25 1 0.5 4 AMP - - 
8 16 32 8 0.12 32 0.12 1 16 1 0.03 8 16 1 1 2 4 AMP,CAR, 
DO, PRL 
+ + 
9 32 32 8 0.12 32 0.12 0.25 8 1 0.015 8 32 0.5 1 0.5 8 AMP + + 
10 64 32 8 0.12 32 >128 >128 >12
8 
0.12 0.015 8 16 0.25 1 0.5 4 AMP,CAR, 
PRL 
+ - 
11 32 32 8 0.12 32 0.03 0.25 4 0.25 0.015 8 64 0.25 1 >128 4 AMP,CAR, 
DO 
+ + 
12 64 32 8 0.12 32 0.12 0.25 16 0.12 0.06 4 16 0.5 1 0.5 16 AMP, DO + + 
13 32 32 8 0.25 32 0.03 0.12 4 0.12 0.015 4 32 0.25 1 0.5 8 AMP + - 
14 4 16 8 0.12 32 0.12 0.25 8 0.12 0.015 4 8 0.25 1 0.12 8  - - 
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16 8 32 8 0.5 64 0.12 0.5 8 0.12 0.015 8 64 0.25 1 0.25 4 AMP + - 




18 64 64 8 0.25 32 0.06 0.5 16 0.25 0.015 8 16 0.25 1 0.5 4 AMP, CAR, 
DO, PRL 
+ - 
19 64 32 8 0.12 32 0.06 0.25 4 0.25 0.015 8 32 0.25 1 0.5 4 AMP + - 
20 32 32 16 0.5 32 0.06 0.12 8 0.25 0.015 8 32 0.25 1 0.5 4 AMP, CAR, 
DO 
+ + 
21 32 32 8 0.12 32 0.03 0.12 4 0.5 0.03 8 32 0.25 1 0.5 4 AMP, DO + + 
22 64 32 8 0.12 32 0.12 0.25 4 0.5 0.015 8 32 0.25 1 0.5 4 AMP, CAR, 
DO, PRL 
+ + 
23 64 32 16 0.5 32 0.03 0.12 2 0.25 0.015 8 64 0.25 1 0.5 4 AMP, CAR, 
DO, PRL 
+ - 
24 128 64 8 0.5 32 0.03 0.5 4 0.25 0.03 8 64 0.25 1 0.5 8 AMP, CAR, 
DO, PRL, E 
+ + 
25 64 16 8 0.5 32 0.06 0.25 8 0.12 0.03 8 32 0.25 2 0.5 4 AMP, CAR + qac
E 




27 64 16 8 0.12 32 >128 64 8 0.5 0.03 8 32 0.12 1 0.5 8 AMP, CAR, 
DO, PRL 
+ - 
28 64 64 8 0.12 64 0.25 1 8 0.25 0.03 8 32 0.25 1 128 8 AMP, CAR, 
DO, PRL, E 
+ + 
29 32 32 8 0.5 32 0.06 1 16 0.25 0.015 8 64 0.25 1 0.5 4 AMP, CAR, 
PRL 
+ - 
30 32 32 8 0.12 32 0.06 1 8 1 0.03 4 64 1 1 0.5 8 AMP, CAR, 
DO, PRL 
+ + 
31 32 64 8 0.12 64 0.03 0.5 4 0.25 0.015 4 32 0.25 1 0.5 4 AMP, DO + + 
32 32 64 16 0.5 32 0.12 0.12 4 0.12 0.015 4 32 0.25 1 0.5 4 AMP, DO + - 
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33 32 32 8 0.12 32 0.06 0.25 8 0.12 0.015 4 32 0.25 1 0.5 8 AMP, DO + - 
34 32 32 8 0.12 32 0.06 0.25 8 0.25 0.03 4 16 0.12 1 >128 4 AMP, CAR, 
DO, PRL 
+ + 
35 32 32 4 0.12 32 0.12 0.25 8 0.5 0.03 8 16 0.25 1 0.5 4 AMP, CAR, 
DO, PRL 
+ + 
36 32 32 8 0.12 32 0.06 0.5 16 1 0.03 8 32 0.5 1 0.5 8 AMP, CAR, 
DO, PRL 
+ + 
37 128 32 8 0.12 32 0.06 0.5 8 0.12 0.015 8 32 0.5 1 0.5 8 AMP, CAR, 
DO, E 
+ - 
38 32 32 8 0.12 32 0.12 0.5 16 1 0.03 4 16 4 1 1 8 AMP, CAR, 
DO, PRL 
+ + 




40 32 32 16 0.12 32 >128 64 8 0.12 0.03 8 32 64 1 >128 4 AMP, CAR + + 
41 64 16 8 0.12 32 0.5 64 16 0.5 0.015 4 16 0.25 1 0.25 4 AMP + - 
42 32 32 8 0.12 64 >128 64 4 0.25 0.015 4 32 0.25 1 0.5 8 AMP, CAR, 
DO, PRL 
- - 
43 32 32 8 0.12 32 0.06 0.25 4 0.5 0.015 8 32 0.25 1 0.5 8 AMP + + 
44 64 32 8 0.25 32 0.06 0.12 8 0.25 0.03 4 32 0.5 2 0.25 4 AMP, CAR, 
DO 
+ + 
45 64 32 16 0.25 32 0.12 0.25 4 0.12 0.015 8 32 0.25 1 0.5 4  + + 
46 64 16 16 0.25 32 0.06 0.25 8 0.25 0.03 4 32 0.25 4 0.5 4 AMP, CAR, 
DO 
+ + 
47 32 16 8 0.5 32 0.03 0.12 8 0.25 0.015 4 16 0.5 1 0.5 4 AMP, CAR + - 
48 64 32 8 0.5 64 >128 128 >12
8 
1 0.015 4 16 0.5 0.5 8 4 AMP, CAR, 
NV, PRL 
+ + 
49 16 32 4 0.5 16 0.06 0.25 4 0.5 0.015 4 64 0.5 2 0.5 4 AMP, CAR, 
DO 
+ + 
50 32 32 16 0.12 16 0.03 0.25 4 0.5 0.015 8 32 0.25 1 0.25 4 AMP + - 
51 32 32 16 0.12 64 0.12 0.5 8 1 0.03 4 64 0.5 1 0.5 4 AMP + - 
52 128 64 16 0.5 64 0.5 1 64 1 0.015 4 64 0.25 1 16 >128 AMP, CAR, 





53 64 16 16 0.12 32 0.03 0.5 32 0.25 0.015 4 32 0.25 1 0.5 4 AMP, CAR + - 
54 64 32 8 0.12 16 0.06 0.25 8 1 0.015 4 32 0.25 1 0.5 4 AMP, CAR + - 
55 32 64 8 0.12 64 0.03 0.25 4 0.25 0.015 4 32 0.25 1 0.5 4 AMP - - 
56 16 64 8 0.12 64 0.5 0.5 32 0.25 0.015 4 32 0.25 1 8 128 AMP, CAR, 
DO, PRL 
+ + 
57 32 64 16 0.12 32 0.5 0.5 32 0.25 0.03 4 32 0.5 1 0.5 4 AMP, CAR + + 
58 16 16 4 0.12 32 0.5 1 8 0.5 0.06 8 32 0.25 1 0.5 4 AMP, CAR, 
DO, PRL 
+ - 
59 32 32 4 0.12 32 0.06 0.25 16 0.12 0.015 4 32 0.5 1 0.5 8 AMP, CAR + - 
60 32 32 8 0.12 64 0.06 0.25 4 0.25 0.015 4 32 0.5 1 0.5 4 AMP, CAR, 
DO 
+ - 
61 32 64 8 0.12 64 0.06 1 8 0.5 0.015 8 64 0.5 8 8 16 AMP, CAR, 
DO, PRL 
- - 
62 32 32 8 0.12 32 0.03 0.25 4 0.25 0.015 2 32 0.25 1 0.25 4 AMP - - 
63 16 32 8 0.12 32 0.06 0.25 4 0.25 0.015 4 32 0.5 1 0.25 4 AMP, CAR, 
DO, NET 
+ + 
64 64 64 16 >128 32 0.06 0.25 8 0.12 0.015 4 64 0.5 1 0.5 4 AMP, CAR + + 
CHX, Chlorhexidine; MH-4, MediHex-4; MS, Mediscrub; BZK, Benzalkonium chloride; CTX, Cefotaxime; CTZ, Ceftazidime; 
CXT, Cefoxitin; IMP, Imipenem; MEM, Meropenem; COL, Colistin; RIF, Rifampicin; GEN, Gentamicin; Poly-B, Polymyxin B; 
TRI, Trimethoprim; CHL, Chloramphenicol.                                                                                                                                                                                                                                                               













































































This study assessed the susceptibility of five biocides, chlorhexidine (CHX), Benzalkonium 
chloride (BZK), Trigene, MediHex-4 (MH-4), Mediscrub (MS) and 17 antibiotics against 64 
isolates of Klebsiella pneumoniae. The relationship between resistance to biocides and the 
carriage of antiseptic resistance genes, cepA, qacΔE and qacE was determined. Antimicrobial 
susceptibility was tested by the agar double dilution method (DDM) and disk diffusion methods. 
The bacteria were not widely resistant except to some beta–lactams. Biocides susceptibility, 
tested by DDM showed that 50, 49 and 53 strains were resistant to CHX, Trigene and BZK 
respectively. The antiseptic resistance genes cepA, qacΔE and qacE were found in 56, 34 and 1 
isolates respectively and their effects as efflux pumps was determined by carbonyl cyanide m-
chlorophenyl hydrazone (CCCP) (10mg/L), which decreased the MICs of CHX and MH-4 by 2-
128 fold but it had no impact on BZK, TG and MS. These results show there was a close link 
between carriage of efflux pump genes, cepA, qacΔE and qacE genes and high-level biocide, 
but not antibiotic, resistance in K. pneumoniae clinical isolates  
Methods and Materials 
Bacterial strains: Klebsiella pneumoniae (64) were isolated from the Royal Infirmary in 
Edinburgh between 2006 and 2008.  
MIC and disk diffusion: Antimicrobial susceptibility was tested by the agar double dilution 
method (DDM) and disk diffusion methods. following the guidelines of British Society for 
Antimicrobial Chemotherapy (BSAC)[1,2].  Biocides susceptibility was tested by DDM 
Efflux pumps inhibitor and biocides resistance: Carbonyl cyanide m-chlorophenylhydrazone 
(CCCP) 10mg/L add to IST agar. 
PCR: The antiseptic resistance genes cepA, qacΔE and qacE were detected by PCR. cepA 
primer pairs amplified 1051 pair base (bp)  were described by Fang et al [3]. The qacΔE and 
qacE primer pairs amplified 370 and 350 bp respectively, all having the same annealing 
temperature 49ºC for 40s, were described by Kazama et al [4].  
Results 
Biocides susceptibility, tested by DDM showed that 50, 49 and 53 strains were resistant to 
CHX, Trigene and BZK respectively. All strains were resistant to MH-4 and sensitive to MS. 
The antiseptic resistance genes cepA, qacΔE and qacE were found in 56, 34 and 1 isolates 
respectively. There was an association of resistance with the cepA and, to a lesser extent, 
qacΔE gene. The role of these efflux pumps in conferring resistance was determined by 
carbonyl cyanide m-chlorophenyl hydrazone (CCCP) (10mg/L), which decreased the MICs 
of CHX and MH-4 by 2-128 fold but it had no impact on BZK, TG and MS.  
 
Conclusion 
These results show there was a close link between carriage of efflux pump genes, cepA, 
qacΔE and qacE genes and high-level biocide resistance in K. pneumoniae clinical 
isolates. 
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Aim 
This study investigates the correlation between biocides use and its association with the genes 
responsible for antiseptics resistance efflux pump genes (cepA, qacΔE, qacE) and resistance genes 
responsible for antibiotics resistance. 
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